



UNIVERSITI PUTRA MALAYSIA

***IN VIVO EVALUATION OF ANTINOCICEPTIVE ACTIVITIES OF
2-BENZOYL-6-(3,4-DIHYDROXYBENZYLIDENE)CYCLOHEXEN-1-OL
AND ITS POSSIBLE MECHANISM OF ACTIONS***

AHMAD FARHAN BIN AHMAD AZMI

FPSK(p) 2022 42



***IN VIVO* EVALUATION OF ANTINOCICEPTIVE ACTIVITIES OF 2-BENZOYL-6-(3,4-DIHYDROXYBENZYLIDENE)CYCLOHEXEN-1-OL AND ITS POSSIBLE MECHANISM OF ACTIONS**

By

AHMAD FARHAN BIN AHMAD AZMI

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Doctor of Philosophy

September 2021

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

***IN VIVO* EVALUATION OF ANTINOCICEPTIVE ACTIVITIES OF 2-BENZOYL-6-(3,4-DIHYDROXYBENZYLIDENE)CYCLOHEXEN-1-OL AND ITS POSSIBLE MECHANISM OF ACTIONS**

By

AHMAD FARHAN BIN AHMAD AZMI

September 2021

Chair : Mohd Roslan Sulaiman, PhD
Faculty : Medicine and Health Sciences

The present study examined the potential antinociceptive activity of 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexene-1-ol (BDC) and its possible mechanism of actions in mice models. BDC, a novel synthetic curcuminoids was freshly prepared and used throughout this experiment. The experimental models were conducted using 6 male ICR mice per group and the one-way analysis of variance (ANOVA) was used to analysed the gathered data by running Tukey's post hoc test with $p < 0.05$, $p < 0.01$ and $p < 0.001$ for statistically significant different. Based on toxicological studies, BDC showed a Lethal does 50 (LD50) greater than 2000 mg/kg sand categorized 5 according to Globally Harmonized System for the classification of chemicals. The oral administration of BDC at doses of 1-30 mg/kg followed by 7 days consecutive observation did not show any death occurrence or any signs of toxicity. The body weights, liver and kidneys, hematological and liver function parameters showed no sign of abnormality. The findings were further supported by the histopathological observations of the liver, kidney and spleen that demonstrated normal histological structure. The determination of the antinociceptive profiles of BDC were through acetic acid-induced abdominal writhing test and hot plate on mice. BDC shown significant inhibitory activity of pain and prolonged time latency on hot plate, suggesting the possible involvement of BDC in both peripheral and central systems of the pain pathway. The rota-rod evaluation confirmed that the antinociceptive effects of BDC were not associated to any non-specific sedative effects such as muscle relaxant or sedation. Further evaluation with formalin-induced paw licking test demonstrated that BDC interacts with opioid receptors in both phases. The study continued to demonstrate the ability of BDC to inhibit pain through the nitric oxide pathway inactivating a series of event involving the L-Arginine-NO-cGMP-K⁺-ATP channel pathways in the acetic acid-induced abdominal writhing test. BDC also showed interactions with two other receptors mainly the NMDA and TRPV1 receptors. Moreover, BDC interacts with other

prominent receptors involved in antinociception including GABAergic, cholinergic, dopaminergic, noradrenergic, serotonergic and adenosinergic systems. The mechanism of action of BDC was further evaluated with the involvement of the Ca²⁺ activated potassium channels, eventually confirming the involvement of the small and large conductance calcium-gated K⁺ channels, voltage-gated K⁺ and ATP-gated K⁺ channels. The involvement of inflammatory mediators on BDC antinociceptive was evaluated using various inflammatory chemical mediators that act as inducers, mainly bradykinin, histamine, serotonin, substance P, phospholipase A₂, prostaglandin E₂ and arachidonic acid, of which BDC at all doses significantly suppressed inflammatory mediators-induced inflammation in all inflammatory chemical mediators-induced experiments. As a conclusion, BDC exerted antinociceptive activity by modulating the activation of various receptors, ion channels, L-arginine-nitric oxide-cGMP pathway and descending inhibitory pathways.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia
sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**PENILAIAN *IN VIVO* TERHADAP AKTIVITI ANTINOSISEPTIF 2-BENZOYL-
6-(3,4-DIHYDROXYBENZYLIDENE)CYCLOHEXEN-1-OL SECARA DAN
KEMUNGKINAN MEKANISMA TINDAKANNYA**

Oleh

AHMAD FARHAN BIN AHMAD AZMI

September 2021

Pengerusi : Mohd Roslan Sulaiman, PhD
Fakulti : Perubatan dan Sains Kesihatan

Kajian ini dijalankan untuk mengenalpasti potensi kesan antinosiseptif 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexene-1-ol (BDC) secara *in vivo* dan kemungkinan mekanisme tindakan terhadap model mencit. BDC merupakan sebatian daripada kurkuminoid sintetik dan telah disediakan dan digunakan sepanjang kajian ini. Model eksperimen telah dijalankan menggunakan 6 tikus ICR jantan bagi setiap kumpulan dan analisis varians sehala (ANOVA) digunakan untuk menganalisis data yang dikumpul melalui ujian post hoc Tukey dengan indikasi $p < 0.05$, $p < 0.01$ dan $p < 0.001$ sebagai statistik yang ketara perbezaannya. Berdasarkan kajian toksikologi, dos maut 50 BDC adalah lebih daripada 2000 mg/kg dan dikategorikan sebagai kategori 5 mengikut Sistem Harmonis Global bagi klasifikasi bahan kimia. Pemberian BDC melalui mulut pada dos 1-30 mg/kg diikuti oleh 7 hari pemerhatian berturut-turut tidak menunjukkan sebarang kematian atau tanda-tanda keracunan. Berat tubuh, hati, ginjal, parameter hematologi dan fungsi hati tidak menunjukkan tanda-tanda toksik atau kesan sampingan yang bahaya. Penemuan ini telah disokong oleh struktur histologi yang normal berdasarkan pemerhatian histopatologi hati, buah pinggang dan limpa. Kajian kesan antinosiseptif BDC terhadap mencit diteruskan lagi menggunakan ujian pencerutan abdomen daripada aruhan asid asetik dan ujian piring panas. BDC menunjukkan perencatan kesakitan yang ketara dan masa pendam yang lama di atas plat panas, hal ini menunjukkan kemungkinan penglibatan BDC dalam kedua-dua sistem saraf periferi dan sistem saraf pusat. Penilaian rota-rod telah mengesahkan bahawa kesan antinosiseptif BDC tidak melibatkan kesan sedatif yang tidak spesifik seperti kesan penenang otot atau sedasi. Penilaian lanjut melalui ujian jilatan kaki yang diaruh oleh formalin menunjukkan bahawa BDC saling tindak terhadap reseptor opioid pada fasa pertama dan fasa kedua. Kajian ini diteruskan dengan membuktikan keupayaan BDC untuk mengurangkan kesakitan melalui sistem nitrik oksida, dengan penglibatan sistem L-Arginina-NO-cGMP-K⁺-ATP dalam ujian penggeliatan abdomen daripada aruhan asid

asetik. BDC juga saling tindak dengan dua reseptor lain terutamanya reseptor NMDA dan TRPV1. Selain itu, BDC juga saling tindak terhadap reseptor-reseptor yang lain termasuk sistem asid gama-aminobutirik, kolinergik, dopaminergik, noradrenergik, serotonergik dan adenosinergik dalam antinosiseptif BDC. Mekanisme tindakan BDC dinilai terhadap saling tindak saluran-saluran ion K^+ yang diaktifkan oleh ion Ca^{2+} , dan seterusnya mengesahkan penglibatan saluran K^+ kalsium yang beraliran kecil dan besar, saluran voltan K^+ dan saluran ATP K^+ . Kajian penglibatan pengantara inflamasi pada antinosiseptif BDC telah dinilai menggunakan pelbagai pengantara inflamasi sebagai aruhan, terutamanya bradikinin, histamin, serotonin, bahan P, fosfolipase A2, prostaglandin E2 dan asid arakidonik, di mana BDC pada semua dos menunjukkan kesan pengurangan kesakitan yang ketara dalam semua eksperimen yang diaruh oleh pengantara inflamasi. Sebagai kesimpulan, kajian ini telah mengesahkan aktiviti-aktiviti antinosiseptif dan juga mekanisme-mekasnisme tindakan yang terlibat melalui sebatian BDC.

ACKNOWLEDGEMENTS

Alhamdulillah, all praise to Allah S.W.T the almighty, for giving me blessings, the strength and the chance for the completion of this thesis. This thesis becomes a reality with the help of many individuals and I would like to extend my sincere thanks to all of them.

First and foremost, I would like to express my utmost gratitude to my supervisor, Prof. Dr. Mohd Roslan Sulaiman, for his guidance and support throughout my research. His unconditional support, guidance, and overall insight in this field, I managed to finish this research project successfully.

Besides my supervisor, I would like to thank my co-supervisors, Prof. Dr. Faridah Abas and Associate Prof. Dr. Enoch Kumar Perimal for imparting their knowledge and expertise in this field of study.

I would also like to express my deepest gratitude to my family, especially my parents, Ahmad Azmi Bin Abd Rahman and Zainun Binti Sulaiman, for their unwavering love, encouragement and emotional support throughout my research and writing my project. They become my source of inspiration to further this study.

Last but not least, I would like to thank physiology laboratory staff and fellow laboratory mates, Madam Norhayati Sulaiman, Madam Hasnijah Alias @ Yaakub, Mr Nasrul Ridzal Zainal Abidin, Ong Hui Ming, Nor 'Adilah Makhtar and Syamimi Khalid, whom have lending me their valuable assistance during my research.

I certify that a Thesis Examination Committee has met on 21 September 2021 to conduct the final examination of Ahmad Farhan bin Ahmad Azmi on his thesis entitled "*In vivo* Evaluation of 2-Benzoyl-6-(3,4-Dihydroxybenzylidene) Cyclohexene-1-ol and its Possible Mechanism of Actions" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the (insert the name of relevant degree).

Members of the Thesis Examination Committee were as follows:

Muhammad Nazrul Hakim bin Abdullah, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Mohamad Aris bin Mohd Moklas, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Zulkhairi Hj Amom, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(External Examiner)

Aydin Him, PhD

Professor
Faculty of Medicine and Health Sciences
Bolu Abant Izzet Baysal University
Turkey
(External Examiner)

ZURIATI AHMAD ZUKARNAIN, PhD

Professor Ts and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 23 December 2021

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Mohd Roslan bin Sulaiman, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Enoch Kumar a/I Perimal, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Faridah binti Abas, PhD

Professor
Faculty of Food Science and Technology
Universiti Putra Malaysia
(Member)

ZALILAH MOHD SHARIFF, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 20 January 2022

Declaration by Members of the Supervisory Committee

This is to confirm that:

- the research and the writing of this thesis were done under our supervision;
- supervisory responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2015-2016) are adhered to.

Signature: _____
Name of Chairman
of Supervisory
Committee: Prof. Dr. Mohd Roslan Sulaiman

Signature: _____
Name of Member of
Supervisory
Committee: Associate Prof. Dr. Enoch Kumar Perimal

Signature: _____
Name of Member of
Supervisory
Committee: Prof. Dr. Faridah Abas

TABLE OF CONTENTS

	Page
ABSTRACT	i
ABSTRAK	iii
ACKNOWLEDGEMENTS	v
APPROVAL	vi
DECLARATION	vii
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF ABBREVIATIONS	xix
CHAPTER	
1	
INTRODUCTION	1
1.1 Background of study	1
1.2 Problem Statements	2
1.3 Study Objectives	4
1.4 Study Hypotheses	4
2	
LITERATURE REVIEW	5
2.1 Pain	5
2.1.1 Nociceptors	6
2.1.2 Nociception Neurons	6
2.1.3 Transmission of Pain Information	7
2.2 Inflammation	9
2.2.1 Inflammatory Response and Pain Pathway	10
2.3 Analgesics Compounds	13
2.3.1 Opioid Analgesic Compounds	13
2.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	14
2.3.3 Mechanism of Action of NSAIDs	15
2.4 Other Drug Receptors	16
2.4.1 TRPV1 Receptors	16
2.4.2 GABAergic Receptors	17
2.4.3 Glutamate Receptors	18
2.4.4 Cholinergic Receptors	19
2.4.5 Dopaminergic Receptors	20
2.4.6 Noradrenergic Receptors	21
2.4.7 Serotonergic Receptors	22
2.4.8 Adenosinergic Receptors	23
2.5 Nitric Oxide and cGMP Involvement in Pain Modulation	24
2.6 Role of Ca ²⁺ Activated Potassium Channel	25
2.7 Analogue based-drug discovery	26
2.7.1 Curcumin as Potential Therapeutic Analgesic	27
2.7.2 Curcuminoid Analogue as Potential Therapeutic Analgesic	30

2.7.3	2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDC)	31
3	ACUTE TOXICITY ANALYSIS OF BDC IN MICE	33
3.1	Introduction	33
3.2	Materials and Methods	34
3.2.1	Synthesis of BDC	34
3.2.2	Preparation of BDC	35
3.2.3	Preparation of Drugs	35
3.2.4	Acute Oral Toxicity Assessment	35
3.2.5	Statistical Analysis	38
3.2	Results	39
3.3	Discussion	47
3.4	Conclusion	49
4	DETERMINATION OF THE ANTINOCICEPTIVE PROFILES OF BDC	50
4.1	Introduction	50
4.2	Materials & Methods	50
4.2.1	Experimental Animals	50
4.2.2	Preparation of Drugs	50
4.2.3	Preparation of BDC	51
4.2.4	Acetic Acid-induced Abdominal Writhing Test	51
4.2.5	Formalin-induced Paw Licking Test	51
4.2.6	Motor Coordination Evaluation	51
4.2.7	Statistical Analysis	52
4.3	Results	52
4.4	Discussion	56
4.5	Conclusion	59
5	EVALUATION OF THE INVOLVEMENT OF INFLAMMATORY MEDIATORS IN ANTINOCICEPTIVE ACTIVITY OF BDC	60
5.1	Introduction	60
5.2	Materials & Methods	61
5.2.1	Experimental Animals	61
5.2.2	Preparation of Drugs	61
5.2.3	Preparation of BDC	61
5.2.4	Bradykinin-Induced Nociception Test	61
5.2.5	Phospholipase A2-Induced Nociception Test	61
5.2.6	Arachidonic Acid-Induced Nociception Test	62
5.2.7	Histamine-Induced Nociception Test	62
5.2.8	Serotonin-Induced Nociception Test	62
5.2.9	Prostaglandin E2-Induced Nociception Test	62
5.2.10	Statistical Analysis	63
5.3	Results	63

5.4	Discussion	68
5.5	Conclusion	74
6	EVALUATION OF TRPV1 RECEPTORS, GLUTAMATE RECEPTORS AND L-ARGININE - NITRIC OXIDE - CYCLIC GUANOSINE MONOPHOSPHATE -K⁺-ATP CHANNEL PATHWAY IN ANTINOCICEPTIVE ACTIVITY OF BDC	75
6.1	Introduction	75
6.2	Materials & Methods	76
6.2.1	Experimental Animals	76
6.2.2	Preparation of Drugs	76
6.2.3	Preparation of BDC	76
6.2.4	Capsaicin-induced Nociception Test	76
6.2.5	Glutamate-induced Nociception Test	76
6.2.6	Involvement of the L-Arginine-Nitric Oxide Pathway	76
6.2.7	Involvement of cyclic Guanosine Monophosphate	77
	(cGMP)	
6.2.8	Statistical Analysis	77
6.3	Results	78
6.4	Discussion	81
6.5	Conclusion	86
7	EVALUATION OF THE INVOLVEMENT OF OPIOID RECEPTORS IN ANTINOCICEPTIVE ACTIVITY OF BDC	87
7.1	Introduction	87
7.2	Materials & Methods	88
7.2.1	Experimental Animals	88
7.2.2	Preparation of Drugs	88
7.2.3	Preparation of BDC	88
7.2.4	Hot Plate Test	88
7.2.5	Involvement of Opioid Receptors	89
7.2.6	Statistical Analysis	89
7.3	Results	89
7.4	Discussion	96
7.5	Conclusion	98
8	EVALUATION OF THE INVOLVEMENT OF POTASSIUM CHANNELS IN ANTINOCICEPTIVE ACTIVITY OF BDC	99
8.1	Introduction	99
8.2	Materials & Methods	100
8.2.1	Experimental Animals	100
8.2.2	Preparation of Drugs	100
8.2.3	Preparation of BDC	100
8.2.4	Involvement of ATP-Sensitive K ⁺ Channel	100

8.2.5	Involvement of Voltage-Gated K ⁺ Channel	100
8.2.6	Involvement of Large Conductance Ca ²⁺ -Activated K ⁺ Channel	101
8.2.7	Involvement of Small Conductance Ca ²⁺ -Activated K ⁺ Channel	101
8.2.8	Statistical Analysis	101
8.3	Results	102
8.4	Discussion	105
8.5	Conclusion	107
9	EVALUATION OF THE INVOLVEMENT OF GABAERGIC, CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, SEROTONERGIC AND ADENOSINERGIC SYSTEM IN ANTINOCICEPTIVE ACTIVITY OF BDC	108
9.1	Introduction	108
9.2	Materials & Methods	109
9.2.1	Preparation of BDC	109
9.2.2	Preparation of Drugs	109
9.2.3	Experimental Animals	109
9.2.4	Involvement of the GABAergic System	110
9.2.5	Involvement of the Cholinergic System	110
9.2.6	Involvement of the Adenosinergic System	110
9.2.7	Involvement of the Noradrenergic System	110
9.2.8	Involvement of the Dopaminergic System	111
9.2.9	Involvement of the Serotonergic System	111
9.2.10	Statistical Analysis	111
9.3	Results	112
9.4	Discussion	119
9.5	Conclusion	126
10	SUMMARY, GENERAL CONCLUSION AND RECOMMENDATION OF FUTURE RESEARCH	127
10.1	Summary	127
10.2	Conclusion	129
10.3	Recommendations for future studies	129
	REFERENCES	132
	APPENDICES	157
	BIODATA OF STUDENT	171
	LIST OF PUBLICATIONS	172

LIST OF TABLES

Table		Page
3.1	Body weight of the five animals which were administered BDC at concentrations of 175, 550 and 2000 mg/kg in accordance with OECD 425, as well as observations for any behavioural signs of toxicity and occurrence of death at 0-0.5, 1 and 4 h after administration in short- and long-term outcome.	40
3.2	Hematology analysis on erythrogram, platelet count and leukogram parameters on mice after 7-day post-treatment of BDC or vehicle (Normal Group).	42
3.3	Biochemical analysis on liver function test and kidney function test on mice after 7-day post-treatment of BDC or vehicle (Normal Group).	43
7.1	The Effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), morphine (MOR; 5 mg/kg, i.p.) and control (10 ml/kg, i.p.) against hot plate test in mice.	91
7.2	Effect of naloxone (NAL: 5 mg/kg, i.p.) pretreatment on BDC (3 mg/ kg, i.p) and morphine (MOR; 5 mg/kg, i.p.) against hot plate test.	92

LIST OF FIGURES

Figure		Page
1.1	Chemical structure of curcumin	2
1.2	Chemical structure of 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one	3
1.3	Chemical structure of 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol	3
2.1	Fundamental route of pain transmission. Pain pathway involves several stages; transduction, transmission, modulation and perception	12
2.2	The nonsteroidal anti-inflammatory drugs (NSAIDs) prevented the conversion of arachidonic acids to prostaglandins (PGs) through the inhibition of cyclooxygenase isoenzymes COX1 and COX2. The adverse effects from PGs inhibition are listed	16
2.3	Turmeric is extracted from the roots of <i>Curcuma longa</i> rhizomes. As a member of the ginger family, it has been widely used as an herbal medicine, ingredient of cosmetics, and dietary supplement	27
2.4	Chemical structures of curcuminoids found in turmeric	29
2.5	In general, the curcumin molecule consists of two phenolic groups held together by a diketone moiety	30
2.6	Chemical structure of (A) BDC and (B) DHHPD 2-benzoyl-6-(3,4-di- hydroxybenzylidene)cyclohexen-1-ol (BDC) (A) and 5-(3,4 dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl) penta-2,4-dien-1-one (DHHPD) (B). BDC and DHHPD shared a similar 3,4-dihydroxyphenyl ring as circled in red-dash line	32
3.1	Reagents and conditions: (a) p-toluene-sulphonic acid, toluene, reflux (2h); (b) benzoic anhydride, RT (24h); (c) H ₂ O, reflux (0.5h); (d) 3,4-dihydroxybenzaldehyde, acetic acid, H ₂ SO ₄ , RT (overnight)	35
3.2	Histology of liver sections after 7-day single dose acute toxicity test after post-administration of BDC on mice	44
3.3	Histology of kidney sections after 7-day single dose acute toxicity after post-administration of BDC on mice	45

3.4	Histology of spleen sections after 7-day single dose acute toxicity after post-administration of BDC on mice	46
4.1	The Effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), aspirin (ASA; 100 mg/kg, i.p.) and morphine (MOR; 5 mg/kg, i.p.) against acetic acid-induced nociception	54
4.2	Figure 4.2: The antinociceptive effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), and Diazepam (4 mg/kg, i.p.) on the sensorimotor performance of mice in rota-rod test	54
4.3	The antinociceptive effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), Aspirin (ASA; 100 mg/kg, i.p.) and Morphine (MOR; 5 mg/kg, i.p.) against formalin-induced paw licking test in mice	55
5.1	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) on nociception induced by bradykinin in paw licking test in mice models	65
5.2	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) on nociception induced by substance P in paw licking test	65
5.3	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.), and ASA (100 mg/kg, i.p.) on nociception induced by phospholipase A2 in paw licking in mice	66
5.4	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) on nociception induced by arachidonic acid in paw licking test in mice model	66
5.5	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) on nociception induced by PGE2 in paw licking model in mice	67
5.6	The Effects of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) on nociception induced by histamine in paw licking model in mice	67
5.7	The Effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), and ASA (100 mg/kg, i.p.) on nociception induced by serotonin in paw licking in mice	68
6.1	Effect of BDC (1, 3, 10 and 30 mg/kg, i.p.), capsazepine and ASA (100 mg/kg, i.p.) against nociception induced by capsaicin on paw licking test	79
6.2	Effect of BDC (1, 3, 10 and 30 mg/kg, i.p.) and ASA (100 mg/kg, i.p.) against nociception induced by glutamate in paw licking test.	79

6.3	Effect of pre-treatment with L-arginine (100 mg/kg, i.p.) and L-NOARG (20 mg/kg, i.p.) on the antinociceptive profiles of BDC (3 mg/kg, i.p.) against acetic acid-induced abdominal writhing test in mice	80
6.4	Effect of pre-treatment with ODQ (2 mg/kg, i.p.) on the antinociceptive profiles of BDC (3 mg/kg, i.p.) against acetic acid-induced abdominal writhing test in mice	80
7.1	The effects of BDC (1, 3, 10 and 30 mg/kg i.p.) and morphine (MOR: 5 mg/kg, i.p.) administered group against hot plate test	93
7.2	The effects of BDC (3 mg/kg i.p.), morphine (MOR: 5 mg/kg, i.p.), BDC (3 mg/kg, i.p.) + NAL (5 mg/kg, i.p.) and MOR (5 mg/kg, i.p.) + NAL (5 mg/kg, i.p.) administered group against hot plate test in mice	94
7.3	Effects of pre-treatment with naloxone (5 mg/kg, i.p.) on antinociceptive activity of BDC (3 mg/kg, i.p.) and morphine (5 mg/kg, i.p.) in the early phase (panel A) and the late phase (panel B) in formalin-induced paw licking test	95
8.1	The effects of glibenclamide (10 mg/kg, i.p.) pretreatment on antinociceptive profiles of BDC (3 mg/kg, i.p.) against nociception induced by acetic acid on abdominal constriction model in mice	103
8.2	The effects of tetraethylammonium (TEA; 10 mg/kg, i.p.) pretreatment on antinociceptive profiles of BDC (3 mg/kg, i.p.) against nociception induced by acetic acid on abdominal constriction model in mice	103
8.3	The effects of charybdotoxin (0.02 mg/kg, i.p.) pretreatment on antinociceptive profiles of BDC (3 mg/kg, i.p.) against nociception induced by acetic acid on abdominal constriction model in mice	104
8.4	Effect of pre-treatment with apamin (0.02 mg/kg, i.p.) on the antinociceptive profiles of BDC (3 mg/kg, i.p.) against acetic acid-induced abdominal constriction model in mice	104
9.1	Analysis of GABAergic involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	114
9.2	Analysis of GABAergic involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	114

9.3	Analysis of Cholinergic involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	115
9.4	Analysis of Adenosinergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	115
9.5	Analysis of noradrenergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	116
9.6	Analysis of noradrenergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	116
9.7	Analysis of dopaminergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	117
9.8	Analysis of serotonergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	117
9.9	Analysis of serotonergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	118
9.10	Analysis of serotonergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	118
9.11	Analysis of serotonergic system involvement on BDC-induced antinociceptive effects in acetic acid-induced abdominal constriction model	119
10.1	Figure 10.1: Schematic diagram of the proposed mechanism of antinociception action demonstrated by BDC.	131

LIST OF ABBREVIATIONS

UPM	Universiti Putra Malaysia
DHHPD	5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl) penta-2,4-dien-1-one
BHMC	2,6-bis-(4-hydroxyl-3-methoxybenzylidene) cyclohexanone
IFN- γ	Interferon gamma
LPS	Lipopolysaccharide
mg/kg	Milligram per kilogram
ml/kg	Milliliter per kilogram
i.p.	Intraperitoneal
i.pl.	Intra plantar
p.o.	Per os
ICR	Institute of cancer research
ANOVA	Analysis of variance
S.E.M.	Standard error mean
IASP	International association for the study of pain
ASA	Acetylsalicylic acid
CAP	Capsazepine
NSAIDs	Non-steroidal anti-inflammatory drugs
CNS	CNS
PNS	Peripheral nervous system
PGE2	Prostaglandin E2
PGE1	Prostaglandin E1
PGA	Prostaglandin A
COX	Cyclooxygenase enzyme
LOX	Lipoxygenase enzyme

COX1	Cyclooxygenase-1
COX2	Cyclooxygenase-2
TRPA1	Transient receptor potential cation channel subfamily A1
TRPV1	Transient receptor potential vanilloid subtype 1
ATP	Adenosine triphosphate
GABA	γ -Aminobutyric acid
GABAA	γ -Aminobutyric acid type A
GABAB	γ -Aminobutyric acid type B
Ca ²⁺	Calcium ion
Na ⁺	Sodium ion
Cl ⁻	Chlorine ion
K ⁺	Potassium ion
iNOS	Inducible nitric oxide synthase
NMDA	N-methyl-D-Aspartate
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
iGluRs	Ionotropic glutamate receptors
mGluRs	Metabotropic glutamate receptors
nAChRs	Nicotinic acetylcholine receptors
mAChRs	Muscarinic acetylcholine receptors
cGMP	Cyclic guanosine monophosphate
CGRP	Calcitonin gene-related Peptide
NaCl	Sodium chloride
5-HT	5-Hydroxytryptamine
TNF- α	Tissue necrotic factor
AR	Adrenergic receptors

GPCR	G protein coupled-receptors
Gi	G protein coupled-receptors - inhibitory
Gq	G protein coupled-receptors - activates the phospholipase C
Gs	G protein coupled-receptors - excitatory
NO	Nitric oxide
NOSs	NO synthases
nNOS	Neuronal NOS
iNOS	Inducible NOS
eNOS	Endothelial NOS
ODQ	1-H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
NK1	Neurokinin-1
NK2	Neurokinin-2
NK3	Neurokinin-3
LD50	Lethal dose 50
EDTA	Ethylenediamine tetra-acetic acid
ALP	Alkaline phosphate
AST	Alanine amino transferase
ALT	Aspartate amino transferase
RBC	Red blood cell count
WBC	White blood cell count
HBG	Hemoglobin concentration
MCH	Mean corpuscular hemoglobin
MCHC	Corpuscular hemoglobin concentration
MCP-1	Monocyte chemoattractant protein
IL-6	Interleukin-6 Gene
IL-10	Interleukin-10 Gene

L-NOARG	N ω -nitro-L-arginine
L-NAME	NG-nitro-L-arginine-methyl ester
RVM	Rostral ventromedial medulla
MOR1	μ 1 receptors
MOR2	μ 2 receptors
Kv	Voltage-gated K ⁺ channels
KCa	Ca ²⁺ -activated K ⁺ channels
BKCa	Large conductance Ca ²⁺ -activated K ⁺ channel

CHAPTER 1

INTRODUCTION

1.1 Background of study

Pain is the most common reason for patients seeking medical consultation. As the population ages, the number of people seeking medical attention of pain such as low back pain and degenerative disorder is expected to increase (Mills et al., 2019). Thus, the use of medication to relieve pain has always been the primary goal among health care practitioners in pain management. Drugs that use to achieve analgesia, a state of pain relief often called as analgesic drugs or painkiller and can be classified into non-steroidal anti-inflammatory drugs (NSAIDs), opioid and analgesic adjuvants. Although the continuous usage of some commercially available drugs of NSAIDs offers effective analgesia in pain management and inflammation, the prolonged use often associated with serious gastrointestinal ulceration complications or possibly resulting in hospitalization and even death (Goldstein & Cryer, 2015). The consistent use of potent narcotic analgesics such as morphine in treating chronic pain can also associate to kidney failure, liver damage or tolerance (Baldini et al., 2012). The adverse effect profiles from available commercial drugs have prompted researchers to find other alternatives for analgesic drugs with equivalent effects and limited side effects.

Since ancient time, plants have always been used in folk medicine as they are the rich source of bioactive compounds with great efficiency and selectivity. Natural source of these bioactive compounds may contain various therapeutic agents that can potentially become active agents in modern drugs application. In the last decades, the plant-based discovery and development as the source of new drugs have been focusing on the identification and isolation of active metabolites in plants. However, despite the success of the natural product in drug discovery, many huge pharmaceutical companies have decreased their emphasis on natural product research programs. This is due to various reasons including limited supply and access as the authorization approval to collect new samples from the country with natural products is difficult due to the law protecting the flora and fauna. Despite the many challenges, the field of natural products have given rise to many discoveries and developments in organic chemistry (Khan, 2018). Chemical modification of bioactive components of naturally occurring metabolites emerged as one of the widely used method to identify new potential drugs with greater efficacy in the pharmaceutical industry. These discoveries help establish synthetic methodologies and also making it possible to create synthetic analogues of the natural product compounds that is better in terms of its pharmacology and pharmaceutical characteristics (Yadav & Purohit, 2013). Therefore, current research is aimed to explore new agents

based on the modifications or derivatives of discovered bioactive components from available plants with remarkable therapeutic activities.

Rhizomes such as turmeric have historically used as a household remedy to treat a number of inflammatory-related conditions and disorders in folk medicine such as bowel disease, pancreatitis and rheumatoid arthritis. In addition to its medicinal properties, turmeric or *Curcuma longa* also gained wide attention among culinary enthusiasts, as it is also used as a seasoning and colouring agent for several food ingredients like mustard, curry, and potato chips (Kumara et al., 2016). Turmeric is composed of several major curcuminoids; curcumin, bisdemethoxycurcumin and demethoxycurcumin. The yellow colour in turmeric is mainly attributed from the presence of these active ingredients (Al-Suhaimi et al., 2011). Among these curcuminoids, curcumin (Figure 1.1) is the dominant polyphenol and responsible for several turmeric's pharmacological activities such as anti-diabetic and anti-inflammatory, as well as exhibits cardio-preventive effect, anti-fertility effect and anti-hypertensive effect (Rahmani et al., 2018). Studies have suggested that two aromatic regions of curcumin might be crucial for potential protein-ligand binding and became a well-accepted design of potential inhibitor (ligand) of protein targets (Lee et al., 2009).




Figure 1.1: Chemical structure of curcumin

1.2 Problem Statement

Although curcumin exhibited excellent anti-inflammatory and antinociceptive activities in vivo and in vitro, the use in medicinal application from curcumin is hindered due to its low bioavailability, solubility and poor absorption rate in the gastrointestinal tract (Sharifi-Rad et al., 2020). Therefore, more research have been done to solve these limitation through various rotes of administration and structural modification of curcumin (Liew et al., 2019). Previously, several diarylpentanoid derivatives from curcuminoids analogues have been successfully synthesized to evaluate their possible anti-inflammatory activity in vitro (Leong et al., 2014). Base from this study, two compound known as 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one (DHHPD) and 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDC) significantly

suppressed the production of nitric oxide (NO) in the interferon gamma (IFN- γ)/lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. In comparison to the other ninety-six compounds produced, DHHPD (Figure 1.2) and BDC (Figure 1.3) was proposed as the most effective compound as anti-inflammatory agents. Moreover, BDC also demonstrated to have higher solubility in water as compared to curcumin, which is one of the major problems that limits the medicinal properties of curcumin. Furthermore, DHHPD also exerted significant anti-inflammatory and antinociceptive agents in vivo. Based from initial screening, diarylpentanoids showed a promising drug candidates as investigational drug to treat both pain and wounds based on significant antinociceptive and anti-inflammatory properties. The results from other diarylpentanoid reports indicated that BDC could highly be a candidate for further investigation on its potential as a new anti-inflammatory and antinociceptive agents since it comes from the same diarylpentanoids family. Therefore, in vivo evaluation of BDC can further strengthen the medicinal potential of diarylpentanoids compound.




Figure 1.2: Chemical structure of 5-(3,4-dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one




Figure 1.3: Chemical structure of 2-benzoyl-6-(3,4-dihydroxy benzylidene) cyclohexen-1-ol

1.3 Study Objectives

The general objectives of this study were to investigate the antinociceptive activities of 2-benzoyl-6-(3,4-dihydroxybenzylidene)cyclohexen-1-ol (BDC) and evaluate the mechanisms of action involved in BDC in animal models.

The specific objectives were as follows:

- 1) To investigate the involvement of opioid receptors in the BDC induced antinociceptive activities.
- 2) To investigate the involvement of non-opioid receptors systems in the BDC induced antinociceptive activities.
- 3) To investigate the role of L-Arginine-NO-cGMP-K⁺ channel pathways in the BDC-induced anti-nociceptive activities.
- 4) To investigate the role of GABAergic, cholinergic, dopaminergic, noradrenergic, serotonergic and adenosinergic systems.
- 5) To investigate the involvement of inflammatory mediators in the BDC-induced anti-nociceptive activities.

1.4 Study Hypotheses

The study hypotheses were as follows:

- 1) BDC exert significant antinociceptive effects through chemical-induced model of preliminary screening.
- 2) BDC does not related to any characteristic of sedative agents and muscular relaxant properties.
- 3) The administration of BDC does not exert toxic effect in mice.
- 4) Opioid receptors are participated in the BDC induced antinociceptive activities.
- 5) Inflammatory mediators are involved in the BDC-induced antinociceptive activities.
- 6) L-Arginine-NO-cGMP-K⁺ channel pathways are involved in the BDC-induced antinociceptive activities.
- 7) GABAergic, cholinergic, dopaminergic, noradrenergic, serotonergic and adenosinergic systems are involved in BDC-induced antinociceptive activities.

REFERENCES

- Abacioğlu, N., Tunctan, B., Akbulut, E., & Cakici, I. (2000). Participation of the components of l-arginine/nitric oxide/cGMP cascade by chemically-induced abdominal constriction in the mouse. *Life Sciences*, 67, 1127-1137.
- Abdel-Hafez, S. M., Hathout, R. M., & Sammour, O. A. (2021). Attempts to enhance the anti-cancer activity of curcumin as a magical oncological agent using transdermal delivery. *ADV TRADIT MED (ADTM)*, 21, 15–29
- Al-Suhaimi, E. A., Al-Riziza, N. A., & Al-Essa, R. A. (2011). Physiological and therapeutical roles of ginger and turmeric on endocrine functions. *The American journal of Chinese medicine*, 39(2), 215-231.
- Alger, B. E., Nagode, D. A., & Tang, A. H. (2014). Muscarinic cholinergic receptors modulate inhibitory synaptic rhythms in hippocampus and neocortex. *Frontiers in Synaptic Neuroscience*, 6, 18.
- Amalraj, A., Pius, A., Gopi, S., & Gopi, S. (2017). Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review. *J Tradit Complement Med.*, 7(2), 205-233.
- Amaya, F., Izumi, Y., Matsuda, M., & Sasaki, M. (2013). Tissue injury and related mediators of pain exacerbation. *Current Neuropharmacology*, 11(6)(6), 592–597.
- Argyrousi, E. K., Heckman, P. R. A., & Prickaerts, J. (2020). Role of cyclic nucleotides and their downstream signaling cascades in memory function: Being at the right time at the right spot. *Neuroscience & Biobehavioral Reviews*, 113, 12-38.
- Arika, W. M., Nyamai, D. W., Musila, M. N., Ngugi, M. P., & Njagi, E. N. M. (2016). Hematological Markers of In Vivo Toxicity. *Journal of Hematology & Thromboembolic Diseases*, 4(2).
- Aroke, E. N., Powell-Roach, K. L., Jaime-Lara, R. B., Tesfaye, M., Roy, A., Jackson, P., & Joseph, P. V. (2020). Taste the Pain: The Role of TRP Channels in Pain and Taste Perception. *International journal of molecular sciences*, 21(16), 5929.
- Asano, T., Dohi, S., & Iida, H. (2000). Antinociceptive Action of Epidural K⁺ ATP Channel Openers via Interaction with Morphine and an 2-Adrenergic Agonist in Rats. *Anesthesia & Analgesia*, 90(5), 1146.
- Asija, R., Prajapat, R., Vyas, P., & Kumar, V. (2014). A brief cause of acute inflammation: an overview. *Journal of Drug Discovery and Therapeutics* 2, 22, 31-35.

- Avila-Rojas, S. H., Velázquez-Lagunas, I., Salinas-Abarca, A. B., Barragán-Iglesias, P., Pineda-Farias, J. B., & Granados-Soto, V. (2015). "Role of spinal 5-HT_{5A}, and 5-HT_{1A/1B/1D}, receptors in neuropathic pain induced by spinal nerve ligation in rats," *Brain Research*, 1622, 377–385.
- Bahari, Z., & Meftahi, G. H. (2019). Spinal α_2 -adrenoceptors and neuropathic pain modulation; therapeutic target. *British journal of pharmacology*, 176(14), 2366–2381.
- Bahia, P. K., Suzuki, R., Benton, D. C. H., Jowett, A. J., Chen, M. X., Trezise, D. J., Dickenson, A. H., & Moss, G. W. J. (2005). A functional role for small-conductance calcium-activated potassium channels in sensory pathways including nociceptive processes. *The Journal of neuroscience*(25), 3489-3498.
- Baldini, A., Korff, M. V., & Lin, E. H. B. (2012). A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide. *The Primary Care Companion for CNS Disorders*, 14(3).
- Banerjee, A., Lee, A., Campbell, E., & MacKinnon, R. (2013). Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K(+) channel. *eLife*, 2, e00594.
- Basile, D. P., Anderson, M. D., & Sutton, T. A. (2014). Pathophysiology of acute kidney injury. *Comprehensive Physiology*, 2(2), 1303–1353.
- Beirith, A., Santos, A. R. S., & Calixto, J. B. (2002). Mechanisms underlying the nociception and paw oedema caused by injection of glutamate into the mouse paw. *Brain research*, 924(2), 219-228.
- Bektas, N., Nemutlu, D., Ulugbay, G., & Arslan, R. (2015). The role of muscarinic receptors in pain modulation. *World Journal of Pharmaceutical and Medical Research*, 1(1), 40–49.
- Bhangoo, S. K., & Swanson, G. T. (2013). Kainate receptor signaling in pain pathways. *Molecular pharmacology*, 83(2), 307–315.
- Bian, K., Ke, Y., Kamisaki, Y., & Murad, F. (2006). Proteomic modification by nitric oxide. *Journal of pharmacological sciences*(0), 608040002.
- Blakemore, D. C., Castro, L., Churcher, I., Rees, D. C., Thomas, A. W., Milson, D. M., & Wood, A. (2018). Organic synthesis provides opportunities to transform drug discovery. *Nature Chem*, 10, 383–394.
- Blunck, R., & Batulan, Z. (2012). Mechanism of electromechanical coupling in voltage-gated potassium channels. *Frontiers in pharmacology*, 3(166).
- Bonezzi, C., Costantini, A., Cruccu, G., Fornasari, D. M. M., Guardamagna, V., Palmieri, V., Polati, E., Zini, P., & Dickenson, A. H. (2020). Capsaicin 8%

dermal patch in clinical practice: an expert opinion. *Expert Opinion on Pharmacotherapy*, 21(11), 1377-1387.

- Brandt, M. R., Beyer, C. E., & Stahl, S. M. (2012). TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. *Pharmaceuticals (Basel, Switzerland)*, 5(2), 114–132.
- Bravo, L., Llorca-Torrallba, M., Berrocoso, E., & Micó, J. A. (2019). Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain. *Frontiers in neuroscience*, 13, 1268.
- Brito, R., Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2014). TRPV1: A Potential Drug Target for Treating Various Diseases. *Cells*, 3(2), 517–545.
- Brown, K. M., Roy, K. K., Hockerman, G. H., Doerksen, R. J., & Colby, D. A. (2015). Activation of the γ -Aminobutyric Acid Type B (GABA(B)) Receptor by Agonists and Positive Allosteric Modulators. *Journal of medicinal chemistry*, 58(16), 6336–6347.
- Brown, R. E., Stevens, D. R., & Haas, H. L. (2001). The physiology of brain histamine. *Progress in neurobiology*, 63(6), 637-672.
- Brune, K., & Patrignani, P. (2015). New insights into the use of currently available non-steroidal anti-inflammatory drugs. *Journal of Pain Research*, 8, 105-118.
- Burke, K. J., & Bender, K. J. (2019). Modulation of Ion Channels in the Axon: Mechanisms and Function. *Front. Cell. Neurosci.*, 13(221). doi:10.3389/fncel.2019.00221
- Burns, J. A., Kroll, D. S., Feldman, D. E., Kure Liu, C., Manza, P., Wiers, C. E., Volkow, N. D., & Wang, G. J. (2019). Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. *Frontiers in psychiatry*, 10, 626.
- Calker, D. V., Biber, K., Domschke, K., & Serchov, T. (2019). The role of adenosine receptors in mood and anxiety disorders. *Journal of Neurochemistry*, 151, 11-27.
- Casey, K. L. (2000). The imaging of pain: background and rationale. *Pain Imaging*, 1-29.
- Castagné, V., Hernier, A. M., & Porsolt, R. D. (2014). CNS Safety Pharmacology. *Reference Module in Biomedical Sciences*, 1-10.
- Caterina, M. J., & Julius, D. (2001). The vanilloid receptor: a molecular gateway to the pain pathway. *Annual Review of Neuroscience*, 24, 487-517.
- Chacur, M., Longo, I., Picolo, G., Gutiérrez, J. M., Lomonte, B., Guerra, J. L., Teixeira, C. F., & Cury, Y. (2003). Hyperalgesia induced by Asp49 and

- Lys49 phospholipases A2 from *Bothrops asper* snake venom: pharmacological mediation and molecular determinants. *Toxicon*, 41(6), 667-678.
- Chalifoux, J. R., & Carter, A. G. (2011). GABAB receptor modulation of synaptic function. *Current opinion in neurobiology*, 21(2), 339–344.
- Chang, C. T., Jiang, B. Y., & Chen, C. C. (2019). Ion Channels Involved in Substance P-Mediated Nociception and Antinociception. *International journal of molecular sciences*, 20(7), 1596.
- Chen, J. F., Eltzschig, H. K., & Fredholm, B. B. (2013). Adenosine receptors as drug targets--what are the challenges? *Nature reviews. Drug discovery*, 12(4), 265–286.
- Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2017). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6), 7204–7218.
- Chen, S. R., & Pan, H. L. (2003). Up-regulation of spinal muscarinic receptors and increased antinociceptive effect of intrathecal muscarine in diabetic rats. *Journal of Pharmacology and Experimental Therapeutics*, 307(2), 676.
- Cheung, C. W., Wong, S. S. C., Qiu, Q., & Wang, X. (2017). Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials. *Pain Physician*, 20.
- Choi, S. I., & Hwang, S. W. (2018). Depolarizing Effectors of Bradykinin Signaling in Nociceptor Excitation in Pain Perception. *Biomolecules & therapeutics*, 26(3), 255–267.
- Choi, S. I., Yoo, S., Lim, J. Y., & Hwang, S. W. (2014). Are sensory TRP channels biological alarms for lipid peroxidation? *Int J Mol Sci.*, 15(9), 16430-16457.
- Chu, Y. C., Guan, Y., Skinner, J., Raja, S. N., Johns, R. A., & Tao, Y. X. (2005). Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent pain. *Pain*, 119, 113–123.
- Comitato, A., & Bardoni, R. (2021). Presynaptic Inhibition of Pain and Touch in the Spinal Cord: From Receptors to Circuits. *International journal of molecular sciences*, 22(1), 414.
- Conrad, K. L., Davis, A. R., Silberman, Y., Sheffler, J., Shields, D., Saleh, A., Sen, N., Matthies, H. J. G., Javitch, J. A., Lindsley, C. W., & Winder, D. G. (2012). Yohimbine Depresses Excitatory Transmission in BNST and Impairs Extinction of Cocaine Place Preference Through Orexin-Dependent, Norepinephrine-Independent Processes. *Neuropsychopharmacology*, 37(10).

- Cortes-Altamirano, J. L., Olmos-Hernandez, A., Jaime, H. B., Carrillo-Mora, P., Bandala, C., Reyes-Long, S., & Alfaro-Rodriguez, A. (2018). Review: 5-HT₁, 5-HT₂, 5-HT₃ and 5-HT₇ Receptors and their Role in the Modulation of Pain Response in the Central Nervous System. *Current neuropharmacology*, 16(2), 210–221.
- Cregg, R., Momin, A., Rugiero, F., Wood, J. N., & Zhao, J. (2010). Pain channelopathies. *The Journal of physiology*, 588(Pt 11), 1897–1904.
- Cury, Y., Picolo, G., Gutierrez, V. P., & Ferreira, S. H. (2011). Pain and analgesia: the dual effect of nitric oxide in the nociceptive system. *Nitric oxide*, 25(3), 243-254.
- de Miranda, F. G. G., Vilar, J. C., Alves, I. A. N., Cavalcanti, S. C. H., & Antonioli, N. R. (2001). Antinociceptive and antiedematogenic properties and acute toxicity of *Tabebuia avellaneda* Lor. ex Griseb. inner bark aqueous extract. *BMC pharmacology*, 1(6).
- De Souza, M. M., Pereira, M. A., Ardenghi, J. V., Mora, T. C., Bresciani, L. F., Yunes, R. A., Delle Monache, F., & Cechinel-Filho, V. (2009). Filicene obtained from *Adiantum cuneatum* interacts with the cholinergic, dopaminergic, glutamatergic, GABAergic, and tachykinergic systems to exert antinociceptive effect in mice. *Pharmacology Biochemistry and Behavior*(93), 40-46.
- Deraedt, R., Jouquey, S., Delevallée, F., & Flahaut, M. (1980). Release of prostaglandins E and F in an algogenic reaction and its inhibition. *European journal of pharmacology*, 61(1), 17-24.
- Desborough, M. J. R., & Keeling, D. M. (2017). The aspirin story – from willow to wonder drug. *British journal of haematology*, 177(5), 674-683.
- Deuis, J. R., Dvorakova, L. S., & Vetter, I. (2017). Methods Used to Evaluate Pain Behaviors in Rodents. *Front. Mol. Neurosci.*, 10, 284.
- Ding, Y., Yao, P., Hong, T., Han, Z., Zhao, B., & Chen, W. (2017). The NO-cGMP-PKG signal transduction pathway is involved in the analgesic effect of early hyperbaric oxygen treatment of neuropathic pain. *The journal of headache and pain*, 18(1), 51.
- Doukkali, Z., Taghzouti, K., Boudida, E. L., Nadjmouddine, M., Cherrah, Y., & Alaoui, K. (2015). Evaluation of anxiolytic activity of methanolic extract of *Urtica urens* in a mice model. *Behavioral and brain functions*, 11(19).
- Dovizio, M., Tacconelli, S., Sostres, C., Ricciotti, E., & Patrignani, P. (2012). Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. *5(12)*, 1346-1371.
- Du, X., & Gamper, N. (2013). Potassium channels in peripheral pain pathways: expression, function and therapeutic potential. *Current Neuropharmacology*(11), 621.

- Du, X., Wang, C., & Zhang, H. E. (2011). Activation of ATP-sensitive potassium channels antagonize nociceptive behavior and hyperexcitability of DRG neurons from rats. *Molecular Pain*(7), 35.
- Dureja, G. P., Iyer, R. N., Das, G., Ahdal, J., & Narang, P. (2017). Evidence and consensus recommendations for the pharmacological management of pain in India. *Journal of pain research*, 10, 709–736.
- Duttaroy, A., Gomeza, J., Gan, J. W., Siddiqui, N., Basile, A. S., Harman, W. D., Smith, P. L., Felder, C. C., Levey, A. I., & Wess, J. (2002). Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. *Molecular pharmacology*, 62(5), 1084.
- Earnest, O. E., Chibueze, P. I., & Emmanuel, E. I. (2018). Advances in acute toxicity testing: strengths, weaknesses and regulatory acceptance. *Interdisciplinary Toxicology*, 11(1), 5-12.
- Ellis, J. L., Harman, D., Gonzalez, J., Spera, M. L., Liu, R., Shen, T. Y., Wypij, D. M., & Zuo, F. (1999). Development of muscarinic analgesics derived from epibatidine: role of the M4 receptor subtype. *Journal of Pharmacology and Experimental Therapeutics*, 288(3), 1143.
- Emily, R. D., & Michael, A. M. (2012). Structure and Regulation of Soluble Guanylate Cyclase. 81(1), 533-559.
- Erami, E., Azhdari-Zarmehri, H., Imoto, K., & Furue, H. (2017). Characterization of Nociceptive Behaviors Induced by Formalin in the Glabrous and Hairy Skin of Rats. *Basic and Clinical Neuroscience*, 8(1), 37-42.
- Everds, N. E. (2015). Evaluation of Clinical Pathology Data: Correlating Changes with Other Study Data. *Toxicologic Pathology*, 43(1), 90-97.
- Faber, E. S., & Sah, P. (2003a). Ca²⁺-activated K⁺ (BK) channel inactivation contributes to spike broadening during repetitive firing in the rat lateral amygdala. *The Journal of Physiology*(552), 483-497.
- Faber, E. S. L., & Sah, P. (2003b). Calcium-activated potassium channels: multiple contributions to neuronal function. *The Neuroscientist*(9), 181-194.
- Fan, S. H., Ali, N. A., & Basri, D. F. (2014). Evaluation of Analgesic Activity of the Methanol Extract from the Galls of *Quercus infectoria* (Olivier) in Rats. *Evidence-Based Complementary and Alternative Medicine*.
- Fields, H. L. (2011). The Doctor's Dilemma: opiate analgesics and chronic pain. *Neuron*, 69(4), 591-594.
- Fisher, C., Johnson, K., Okerman, T., Jurgenson, T., Nickell, A., Salo, E., Moore, M., Doucette, A., Bjork, J., & Klein, A. H. (2019). Morphine Efficacy, Tolerance, and Hypersensitivity Are Altered After Modulation of SUR1

- Subtype KATP Channel Activity in Mice. *Frontiers in neuroscience*, 13, 1122.
- Florentino, I. F., Nascimento, M. V., Galdino, P. M., De Brito, A. F., Da Rocha, F. F., Tonussi, C. R., De Lima, T. C., De Paula, J. R., & Costa, E. A. (2013). Evaluation of analgesic and anti-inflammatory activities of *Hydrocotyle umbellata* L., Araliaceae (acariçoba) in mice. *Anais da Academia Brasileira de Ciencias*, 85(3), 987–997.
- Ford, C. P. (2014). The role of D2-autoreceptors in regulating dopamine neuron activity and transmission. *Neuroscience*, 282, 13–22.
- Freire, M. O., & Van Dyke, T. E. (2013). Natural resolution of inflammation. *Periodontology 2000*, 63(1), 149-164.
- Fuchs, T. C., Frick, K., Emde, B., Czasch, S., Von Landenberg, F., & Hewitt, P. (2012). Evaluation of novel acute urinary rat kidney toxicity biomarker for subacute toxicity studies in preclinical trials. *Toxicologic Pathology*, 40(7), 1031-1048.
- Gadais, C., & Ballet, S. (2020). The Neurokinins: Peptidomimetic Ligand Design and Therapeutic Applications. *Curr. Med. Chem.*, 27, 1515–1561.
- Gangadharan, V., & Kuner, R. (2013). Pain hypersensitivity mechanisms at a glance. *Disease models & mechanisms*, 6(4), 889-895.
- Garland, E. L. (2012). Pain processing in the human nervous system: a selective review of nociceptive and biobehavioral pathways. *Primary care*, 39(3), 561–571. .
- Garmaroudi, F. S., Handy, D. E., Liu, Y. Y., & Loscalzo, J. (2016). Systems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case. *PLoS computational biology*, 12(3).
- George, P., & Hegde, N. (2013). Muscarinic toxicity among family members after consumption of mushrooms. *Toxicology international*, 20(1), 113–115.
- Ghelardini, C., Mannelli, L. D. C., & Bianchi, E. (2015). The pharmacological basis of opioids. *Clinical Cases in Mineral and Bone Metabolism*, 12(3), 219-221.
- Giordano, J., & Schultea, T. (2004). Serotonin 5-HT₃ receptor mediation of pain and anti-nociception: implications for clinical therapeutics. *Pain Physician*(7), 141-147.
- Giovannitti, J. A., Jr., Thoms, S. M., Crawford, J. J., & (2015). . (2015). Alpha-2 adrenergic receptor agonists: a review of current clinical applications. . *Anesthesia progress*, 62(1), 31–39.

- Goldsmith, L. E., & Kwatra, M. M. (2012). NK1 (substance P) receptor. *UCSD Molecule Pages*, 1(1).
- Goldstein, J., & Cryer, B. (2015). Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. *Drug Healthc Patient Saf.*, 7.
- Gouveia, M. G. S., Xavier, M. A., Barreto, A. S., Gelain, D. P., Santos, J. P. A., Araujo, A. A. S., Silva, F. A., Quintans, J. S., Agra, M. F., & Cabral, A. G. S. (2011). Antioxidant, antinociceptive, and anti-inflammatory properties of the ethanolic extract of *Combretum duarceanum* in rodents. *Journal of Medicinal Food*(14), 1389-1396.
- Greene, S. J., Gheorghiu, M., Borlaug, B. A., Pieske, B., Vaduganathan, M., Burnett, J. C., Jr, R., L., Stasch, J. P., Solomon, S. D., & Paulus, W. J. (2013). The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction. *Journal of the American Heart Association*, 2(6).
- Gu, H., Han, S. M., & Park, K.-K. (2020). Therapeutic Effects of Apamin as a Bee Venom Component for Non-Neoplastic Disease. 12(3), 195.
- Gunaydin, C., & Bilge, S. S. (2018). Effects of Nonsteroidal Anti-Inflammatory Drugs at the Molecular Level. *The Eurasian journal of medicine*, 50(2), 116–121.
- Günther, T., Dasgupta, P., Mann, A., Miess, E., Kliewer, A., Fritzwanker, S., Steinborn, R., & Schulz, S. (2018). Targeting multiple opioid receptors - improved analgesics with reduced side effects? *British journal of pharmacology*, 175(14), 2857–2868.
- Gupta, M., Msambichaka, L., Ballas, S. K., & Gupta, K. (2015). Morphine for the treatment of pain in sickle cell disease. *TheScientificWorldJournal*, 540154.
- Hamurtekin, Y., Nouilati, A., Demirbatir, C., & Hamurtekin, E. (2020). The Contribution of Serotonergic Receptors and Nitric Oxide Systems in the Analgesic Effect of Acetaminophen: An Overview of the Last Decade. *Turkish journal of pharmaceutical* \, 17(1), 119–126.
- Hanna, V. S., & Hafez, E. A. A. (2018). Synopsis of arachidonic acid metabolism: A review. *Journal of Advanced Research*, 11, 23-32.
- Harris, R. C., & Zhang, M. Z. (2012). Dopamine, the kidney, and hypertension. . *Current hypertension reports*, 14(2), 138–143.
- Hasbi, A., O'Dowd, B. F., & George, S. R. (2011). Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. *Molecular Brain*, 4(1), 26.

- Hassina, G., Rima, A., Nadia, M., & Abdelouahab, B. (2017). Acute and Subacute Toxicity Evaluation of Alkaloids of *Peganum harmala* L. in Experimental Mice. *International Journal of Pharmacognosy and Phytochemical Research*, 9(9), 1182-1189.
- Herbison, A. E., & Moenter, S. M. (2011). Depolarising and hyperpolarising actions of GABA(A) receptor activation on gonadotrophin-releasing hormone neurones: towards an emerging consensus. *Journal of neuroendocrinology*, 23(7), 557–569.
- Hess, S., Padoani, C., Scorteganha, L. C., Holzmann, I., Malheiros, A., Yunes, R. A., Delle Monache, F., & de Souza, M. M. (2010). Assessment of mechanisms involved in antinociception caused by myrsinoic acid B. *Biological & pharmaceutical bulletin*, 33(2), 209–215.
- Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its' Effects on Human Health. *Foods*, 6(10), 92.
- Hood, D. D., Mallak, K. A., James, R. L., Tuttle, R., & Eisenach, J. C. (1997). Enhancement of analgesia from systemic opioid in humans by spinal cholinesterase inhibition. *Journal of Pharmacology and Experimental Therapeutics*, 282(1), 86.
- Ilie, M. A., Caruntu, C., Tampa, M., Georgescu, S. R., Matei, C., Negrei, C., Ion, R. M., Constantin, C., Neagu, M., & Boda, D. (2019). Capsaicin: Physicochemical properties, cutaneous reactions and potential applications in painful and inflammatory conditions (Review). *Experimental and Therapeutic Medicine*.
- Irifune, M., Sugimura, M., Takarada, T., Maeoka, K., Shimizu, Y., Dohi, T., Nishikawa, T., & Kawahara, M. (1999). Propofol anaesthesia in mice is potentiated by muscimol and reversed by bicuculline. *British Journal of Anaesthesia*(83), 665-667.
- Ismail, N. I., Ming-Tatt, L., Lajis, N., Akhtar, M. N., Akira, A., Perimal, E. P., Israfi, D. A., & Sulaiman, M. R. (2016). Antinociceptive Effect of 3-(2,3-Dimethoxyphenyl)-1-(5-methylfuran-2-yl)prop-2-en-1-one in Mice Models of Induced Nociception. *Molecules*, 21(8), 1077.
- Jackson, W. F. (2017). Potassium Channels in Regulation of Vascular Smooth Muscle Contraction and Growth. *Advances in pharmacology* (San Diego, Calif.), 78, 89–144.
- Jaios, E. S., Rahman, S. A., Ching, S. M., Kadir, A. A., Desa, M. N. M., & Zakaria, Z. A. (2016). Possible mechanisms of antinociception of methanol extract of *Melastoma malabathricum* leaves. *Revista Brasileira de Farmacognosia*, 26(5), 586-594.
- Jang, Y., Kim, M., & Hwang, S. W. (2020). Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. *Journal of Neuroinflammation*, 17(30).

- Jesse, C. R., Rocha, J. B. T., Nogueira, C. W., & Savegnago, L. (2009a). Further analysis of the antinociceptive action caused by p-methoxyl-diphenyl diselenide in mice. *Pharmacology Biochemistry and Behavior*(91), 573-580.
- Jesse, C. R., Savegnago, L., & Nogueira, C. W. (2009b). Mechanisms involved in the antinociceptive and anti-inflammatory effects of bis selenide in mice. *Journal of Pharmacy and Pharmacology*(61), 623-630.
- Jiao, C., Wang, P., Yang, R., Tian, L., & Gu, Z. (2016). IP3 mediates NO-cGMP-induced isoflavone accumulation in soybean sprouts under UV-B radiation. *Journal of Agricultural and Food Chemistry*, 64(44), 8282-8288.
- Jinsmaa, Y., Fujita, Y., & Shiotani, K. (2005). Differentiation of opioid receptor preference by [Dmt1] endomorphin-2-mediated antinociception in the mouse. *European Journal of Pharmacology*, 509(1), 37-42.
- Jinsmaa, Y., Okada, Y., & Tsuda, Y. (2004). Novel 2', 6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic μ -agonists with potent antinociceptive activity in mice. *Journal of Pharmacology and Experimental Therapeutics*, 309(1), 432-438.
- Johnson, M. B., Young, A. D., & Marriott, I. (2017). The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders. *Frontiers in cellular neuroscience*, 10(296).
- Johnston, G. A. R. (2013). Advantages of an antagonist: bicuculline and other GABA antagonists. *British Journal of Pharmacology*, 169, 328-336.
- Johnston, G. A. R. (2014). Muscimol as an Ionotropic GABA Receptor Agonist. *Neurochemical Research*, 39, 1942-1947.
- Julie, G. H. (2006). Serotonin. In G. J. Siegel, R. W. Albers, S. Brady, & D. L. Price (Eds.), *Basic neurochemistry : molecular, cellular, and medical aspects* (7th ed., pp. 227-248). Amsterdam ; Boston: Elsevier Academic Press.
- Kamaldin, M. N., Akhtar, M. N., Mohamad, A. S., Lajis, N., Perimal, E. K., Akira, A., Ming-Tatt, L., Israif, D. A., & Sulaiman, M. R. (2013). Peripheral Antinociception of a Chalcone, Flavokawin B and Possible Involvement of the Nitric Oxide/Cyclic Guanosine Monophosphate/Potassium Channels Pathway. *Molecules*, 18(4), 4209-4220.
- Kamarudin, N., Hisamuddin, N., Ong, H. M., Ahmad Azmi, A. F., Leong, S. W., Abas, F., Sulaiman, M. R., & Shaik Mossadeq, W. M. (2018). Analgesic Effect of 5-(3,4-Dihydroxyphenyl)-3-hydroxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-one in Experimental Animal Models of Nociception. *Molecules* (Basel, Switzerland), 23(9), 2099.

- Kamdi, A. S., Gosavi, D. D., Kalambe, S. M., & Bohra, P. N. (2020). The Motor Coordination Activity Of Aqueous Extract Of Withania Coagulans Fruits In Swiss Albino Mice By Rota Rod Test. *European Journal of Medical and Health Sciences*, 2(3).
- Kannampalli, P., & Sengupta, J. N. (2015). Role of Principal Ionotropic and Metabotropic Receptors in Visceral Pain. *Journal of Neurogastroenterology and Motility*, 21(2), 147-158.
- Kassuya, C. A. L., Ferreira, J., Claudino, R. F., & Calixto, J. B. (2007). Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. *British Journal of Pharmacology*(150), 727-737.
- Keeble, J., Blades, M., Pitzalis, C., Castro da Rocha, F. A., & Brain, S. D. (2005). The role of substance P in microvascular responses in murine joint inflammation. *British journal of pharmacology*, 144(8), 1059–1066.
- Keil, G. J., & Delander, G. E. (2014). Time-dependent antinociceptive interactions between opioids and nucleoside transport inhibitors. *Journal of Pharmacology and Experimental Therapeutics.*, 274(3), 1387–1392.
- Kesim, M., Duman, E. N., Kadioglu, M., Yaris, E., Kalyoncu, N. I., & Erciyes, N. (2005). The different roles of 5-HT2 and 5-HT3 receptors on antinociceptive effect of paroxetine in chemical stimuli in mice. *Journal of Pharmacological Sciences*(97), 6166.
- Khalid, S., & Tubbs, R. S. (2017). *Neuroanatomy and Neuropsychology of Pain*. *Cureus*, 9(10).
- Khan, M. I., & G., H. (2020). Human Secretary Phospholipase A2 Mutations and Their Clinical Implications. *J Inflamm Res.*, 13, 551-561.
- Khan, R. A. (2018). Natural products chemistry: The emerging trends and prospective goals. *Saudi Pharmaceutical Journal*, 26(5), 739-753.
- Khazir, J., Mir, B. A., & Cowan, D. (2013). Natural products as lead compounds in drug discovery. *Journal of Asian Natural Products Research*, 15(7), 764-768.
- Kim, I. J., Park, C. H., Lee, S. H., & Yoon, M. H. (2013). The role of spinal adrenergic receptors on the antinociception of ginsenosides in a rat postoperative pain model. *Korean J. Anesthesiol*(65), 55-60.
- Kirifides, M. L., Simpson, K. L., Lin, R. C. S., & Waterhouse, B. D. (2001). Topographic organization and neurochemical identity of dorsal raphe neurons that project to the trigeminal somatosensory pathway in the rat. *The Journal of Comparative Neurology*, 435(3), 325-340.
- Köhling, R., & Wolfart, J. (2016). Potassium Channels in Epilepsy. *Cold Spring Harbor perspectives in medicine*, 6(5).

- Kotas, M. E., & Medzhitov, R. (2015). Homeostasis, Inflammation, and Disease Susceptibility. *Cell*, 160(5), 816-827.
- Kühner, P., Prager, R., Stephan, D., Russ, U., Winkler, M., Ortis, D., Bryan, J., Quast, U., & 2012;. (2012). Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic KATP channel. *Naunyn-Schmiedeberg's Arch. Pharmacol*, 385;, 299–311.
- Kumamoto, E., Mizuta, K., & Fujita, T. (2011). Opioid Actions in Primary-Afferent Fibers—Involvement in Analgesia and Anesthesia. *Pharmaceuticals*, 4(2), 343-365.
- Kumara, B., Singh, V., Shankar, R., Kumara, K., & Rawal, R. (2016). Synthetic and Medicinal Prospective of Structurally Modified Curcumins. *Current Topics in Medicinal Chemistry*, 16(1), 1-14.
- Lee, K. H., Aziz, F. H. A., Syahida, A., Abas, F., Shaari, K., Israf, D. A., & Lajis, N. H. (2009). Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. *European Journal of Medicinal Chemistry*, 44(8), 3195-3200.
- Lee, M. R., Dukan, E., & Milne, I. (2018). Amanita muscaria (fly agaric): from a shamanistic hallucinogen to the search for acetylcholine. *J R Coll Physicians Edinb*, 48, 85–91.
- Lee, W. H., Loo, C. Y., Bebawy, M., Luk, F., Mason, R. S., & Rohanizadeh, R. (2013). Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. *Current neuropharmacology*, 11(4), 338–378.
- Leong, S. W., Faudzi, S. M., Abas, F., Aluwi, M. F., Rullah, K., Wai, L. K., Bahari, M. N., Ahmad, S., Tham, C. L., Shaari, K., & Lajis, N. H. (2014). Synthesis and sar study of diarylpentanoid analogues as new anti-inflammatory agents. . *Molecules (Basel, Switzerland)*, 19(10), 16058–16081.
- Leong, S. W., Mohd Faudzi, S. M., Abas, F., Mohd Aluwi, M. F., Rullah, K., Lam, K. W., Abdul Bahari, M. N., Ahmad, S., Tham, C. L., Shaari, K., & Lajis, N. H. (2015). Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid and diarylpentanoid derivatives. *Bioorganic & medicinal chemistry letters*, 25(16), 3330–3337.
- Li, C., Sugam, J. A., Lowery-Gionta, E. G., McElligott, Z. A., McCall, N. M., Lopez, A. J., McKlveen, J. M., Pleil, K. E., & Kash, T. L. (2016). Mu Opioid Receptor Modulation of Dopamine Neurons in the Periaqueductal Gray/Dorsal Raphe: A Role in Regulation of Pain. *Neuropsychopharmacology*, 41, 2122–2132.

- Li, P., Snyder, G. L., & Vanover, K. E. (2016). Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. . *Current topics in medicinal chemistry*, 16(29), 3385–3403.
- Liew, K. Y., Rosly, N. A., Abas, F., Leong, S. W., Israf, D. A., & Tham, C. L. (2019). Effect of Diarylpentanoid Analogues on Lipopolysaccharide-Induced Interleukin-6 and Interleukin-8 Gene Expression in Airway Inflammation. *Malaysian Journal of Medicine and Health Sciences*, 10-17.
- Lin, S.-Y., Chang, W.-J., Lin, C.-S., Huang, C.-Y., Wang, H.-F., & Sun, W.-H. (2011). Serotonin receptor 5-HT_{2B} mediates serotonin-induced mechanical hyperalgesia. *The Journal of neuroscience*(31), 1410-1418.
- Lisowska, B., Lisowski, A., & Siewruk, K. (2015). Substance P and Chronic Pain in Patients with Chronic Inflammation of Connective Tissue. *PLOS ONE*, 10(10).
- Lopes, L. d. S., Marques, R. B., Fernandes, H. B., Pereira, S. D. S., Ayres, M. C. C., Chaves, M. H., & Almeida, F. R. C. (2012). Mechanisms of the antinociceptive action of (-) Epicatechin obtained from the hydroalcoholic fraction of *Combretum leprosum* Mart & Eic in rodents. *J Biomed Sc*, 19(68).
- López-Cano, M., Fernández-Dueñas, V., Llebaria, A., & Ciruela, F. (2017). Formalin Murine Model of Pain., 7(23), 2628.
- Lu, R., Lukowski, R., Sausbier, M., Zhang, D. D., Sisignano, M., Schuh, C.-D., Kuner, R., Ruth, P., Geisslinger, G., & Schmidtko, A. (2014). BKCa channels expressed in sensory neurons modulate inflammatory pain in mice. *Pain*, 155(556-565).
- Lv, J., & Liu, F. (2017). The Role of Serotonin beyond the Central Nervous System during Embryogenesis. 11(74).
- Machu, T. K. (2011). Therapeutics of 5-HT₃ receptor antagonists: current uses and future directions. *Pharmacology & therapeutics*, 130(3), 338–347.
- Mahdian Dehkordi, F., Kaboutari, J., Zendejdel, M., & Javdani, M. (2019). The Korean journal of pain. The antinociceptive effect of artemisinin on the inflammatory pain and role of GABAergic and opioidergic systems, 32(3), 160–167.
- Malcangio, M. (2018). GABAB receptors and pain. *Neuropharmacology*, 136, 102–105.
- Mandalà, M., Moro, C., Labianca, R., Cremonesi, M., & Barni, S. (2006). Optimizing use of opiates in the management of cancer pain. *Therapeutics and Clinical Risk Management*, 2(4), 447-453.

- Manion, J., Waller, M. A., Clark, T., Massingham, J. N., & Neely, G. G. (2019). Developing Modern Pain Therapies. *Frontiers in neuroscience*, 13, 1370.
- Marshall, L. A., Chang, J. Y., Calhoun, W., Yu, J., & Carlson, R. P. (1989). Preliminary studies on phospholipase A₂-induced mouse paw edema as a model to evaluate antiinflammatory agents. *Journal of cellular biochemistry*(40), 147-155.
- Mason, P. (1999). Central mechanisms of pain modulation. *Current Opinion in Neurobiology*, 9(4), 436-441.
- McCorvy, J. D., & Roth, B. L. (2015). Structure and function of serotonin G protein-coupled receptors. *Pharmacology & therapeutics*, 150, 129–142.
- McEntire, D. M., Kirkpatrick, D. R., Dueck, N. P., Kerfeld, M. J., Smith, T. A., Nelson, T. J., Reisbig, M. D., & Agrawal, D. K. (2016). Pain transduction: a pharmacologic perspective. *Expert review of clinical pharmacology*, 9(8), 1069–1080.
- Melzack, R., & Wall, P. D. (1967). Pain mechanisms: a new theory. *Survey of Anesthesiology*. 11(2), 89.
- Meotti, F. C., Fachinetto, R., Maffi, L. C., Missau, F. C., Pizzolatti, M. G., Rocha, J. B. T., & Santos, A. R. S. (2007). Antinociceptive action of myricitrin: involvement of the K⁺ and Ca²⁺ channels. *European Journal of Pharmacology*, 567, 198-205.
- Mercado-Reyes, J., Almanza, A., Segura-Chama, P., Pellicer, F., & Mercado, F. (2019). D₂-like receptor agonist synergizes the μ -opioid agonist spinal antinociception in nociceptive, inflammatory and neuropathic models of pain in the rat. *European Journal of Pharmacology*, 853, 56–64.
- Meves, H. (2006). The Action of Prostaglandins on Ion Channels. *Current Neuropharmacology*, 4(1), 41-57.
- Milind, P., & Monu, Y. (2013). Laboratory models for screening analgesic. *International Research Journal of Pharmacy*, 4(1), 15-19.
- Millan, M. J. (2002). Descending control of pain. *Progress in neurobiology*, 66(6), 355-474.
- Mills, S., Nicolson, K. P., & Smith, B. H. (2019). Chronic pain: a review of its epidemiology and associated factors in population-based studies. *British journal of anaesthesia*, 123(2).
- Ming-Tatt, L., Khalivulla, S. I., Akhtar, M. N., Mohamad, A. S., Perimal, E. K., Khalid, M. H., Akira, A., Lajis, N., Israf, D. A., & Sulaiman, M. R. (2012). Antinociceptive activity of a synthetic curcuminoid analogue, 2, 6-bis-(4-hydroxy-3-methoxybenzylidene) cyclohexanone, on nociception-induced

- models in mice. *Basic & clinical pharmacology & toxicology*, 110, 275-282.
- Mino, J., Moscatelli, V., Hnatyszyn, O., Gorzalczy, S., Acevedo, C., & Ferraro, G. (2004). Antinociceptive and antiinflammatory activities of *Artemisia copa* extracts. *Pharmacological Research*, 50(1), 56-63.
- Mishra, A., Singh, S., & Shukla, S. (2018). Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease. *Journal of experimental neuroscience*, 12.
- Mohamad, A. S., Akhtar, M. N., Zakaria, Z. A., Perimal, E. K., Khalid, S., Mohd, P. A., Khalid, M. H., Israf, D. A., Lajis, N. H., & Sulaiman, M. R. (2010). Antinociceptive activity of a synthetic chalcone, flavokawin B on chemical and thermal models of nociception in mice. *European Journal of Pharmacology*, 647, 103-109.
- Morales-Lazaro, S. L., Simon, S. A., & Rosenbaum, T. (2013). The role of endogenous molecules in modulating pain through transient receptor potential vanilloid 1 (TRPV1). *The Journal of Physiology*(591), 3109-3121.
- Morgan, M., Nencini, S., Thai, J., & Ivanusic, J. J. (2019). TRPV1 activation alters the function of A δ and C fiber sensory neurons that innervate bone. *Bone*, 123, 168–175.
- Mukherjee, P., Cinelli, M. A., Kang & S., Silverman, R. B. (2014). Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. *Chemical Society reviews*, 43(19), 6814–6838.
- Mulkiewicz, E., Wolecki, D., Świacka, K., Kumirska, J., Stepnowski, P., & Caban, M. (2021). Metabolism of non-steroidal anti-inflammatory drugs by non-target wild-living organisms. *Science of The Total Environment*, 791.
- Naguib, M., & Yaksh, T. L. (1994). Antinociceptive Effects of Spinal Cholinesterase Inhibition and Isobolographic Analysis of the Interaction with $[\mu]$ and $[\alpha]$ 2 Receptor Systems. *Anesthesiology*, 80(6), 1338.
- Nandy, S., & Datta, R. (2012). Acute and subacute toxicity studies of methanolic leaves extract of *Pterospermum acerifolium* L wild in rodents. *International Journal of Pharmacy and Life Sciences*, 3(3), 1519–1529.
- Negrete, R., Hervera, A., Leánez, S., Martín-Campos, J. M., & Pol, O. (2011). The antinociceptive effects of JWH-015 in chronic inflammatory pain are produced by nitric oxide-cGMP-PKG-KATP pathway activation mediated by opioids. *PLOS ONE*, 6(10).
- Nelson, L. E., Lu, J., Guo, T., Saper, C. B., Franks, N. P., & Maze, M. (2003). The α 2-Adrenoceptor Agonist Dexmedetomidine Converges on an

- Endogenous Sleep-promoting Pathway to Exert Its Sedative Effects. *Anesthesiology*, 98(2), 428-436.
- Nicolaou, K. C., Sanchini, S., Sarlah, D., Gang Lu, G., Wu, T. R., Nomura, D. K., Cravatt, B. F., Cubitt, B., de la Torre, J. C., Hessel, A. J., & Burton, D. R. (2011). Design, synthesis, and biological evaluation of a biyouyanagin compound library. *PNAS*, 108 (17), 6715-6720.
- Norberg, J. K., Sells, E., Chang, H. H., Alla, S. R., Zhang, S., & Meuillet, E. J. (2013). Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂. *Pharmaceutical patent analyst*, 2(2), 265–288.
- North, R. A. (1989). Drug receptors and the inhibition of nerve cells. *British journal of pharmacology*, 98(1), 13.
- O'Donnell, J., Zeppenfeld, D., McConnell, E., Pena, S., & Nedergaard, M. (2012). Norepinephrine: a neuromodulator that boosts the function of multiple cell types to optimize CNS performance. *Neurochemical research*, 37(11), 2496–2512.
- O'Mahony, L., Akdis, M., & Akdis, C. A. (2011). Regulation of the immune response and inflammation by histamine and histamine receptors. *Journal of Allergy and Clinical Immunology*(128), 1153-1162.
- Obata, H. (2017). Analgesic Mechanisms of Antidepressants for Neuropathic Pain. *Int J Mol Sci.*, 18(11), 2483.
- Ocana, M., Cendan, C. M., Cobos, E. J., Entrena, J. M., & Baeyens, J. M. (2004). Potassium channels and pain: present realities and future opportunities. *European Journal of Pharmacology*(500), 203-219.
- Ocaña, M., & Del, P. (1990). An ATP-dependent potassium channel blocker antagonizes morphine analgesia. *European journal of pharmacology*, 186(2-3), 377-378.
- OECD. (2008). Acute Oral Toxicity: Up-and-Down Procedure (UDP), OECD Guidelines for Testing of Chemicals No. 425. 425, 1-2.
- Olayode, O. A., Daniyan, M. O., & Olayiwola, G. (2020). Biochemical, hematological and histopathological evaluation of the toxicity potential of the leaf extract of *Stachytarpheta cayennensis* in rats. *Journal of Traditional and Complementary Medicine*, 10(6), 544-554.
- Onaka, T., Yamashita, T., Liu, X., Honda, K., Saito, T., & Yagi, K. (2001). Medullary A1 noradrenergic neurones may mediate oxytocin release after noxious stimuli. *Neuroreport*, 12(11), 2499.
- Ong, H. M., Mohamad, A. S., Makhtar, N., Khalid, M. H., Khalid, S., Perimal, E. K., Mastuki, S. N., Zakaria, Z. A., Lajis, N., & Israf, D. A. (2011). Antinociceptive activity of methanolic extract of *Acmella uliginosa* (Sw.) Cass. *Journal of ethnopharmacology*, 133, 227-233.

- Oosten, A. W., Oldenmenger, W. H., Mathijssen, H. J., & Van Der Rijt, C. C. D. (2015). A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: A call for the use of standardized outcomes measures. *The Journal of Pain*, 16(10), 935-946.
- Ossipov, M. H., Morimura, K., & Porreca, F. (2014). Descending pain modulation and chronification of pain. *Current opinion in supportive and palliative care*, 8(2), 143–151.
- Oyebanji, B. O., Saba, A. B., & Oridupa, O. A. (2012). Anti-inflammatory and Analgesic effects of Methanol Extract of *Stellaria media* (L.) Vill Leaf. *African Journal of Biomedical Research*, 15, 181-186.
- Parasuraman, S. (2011). Toxicological screening. *Journal of Pharmacology & Pharmacotherapeutics*, 2(2), 74-79. doi:10.4103/0976-500X.81895
- Patel, P. K., Sahu, J., & Chandel, S. S. (2016). A Detailed Review on Nociception Models for the Screening of Analgesic Activity in Experimental Animals. *International Journal of Neurologic Physical Therapy*, 2(6), 44-50.
- Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: an update. *British journal of pain*, 6(1), 11–16.
- Perimal, E. K., Akhtar, M. N., Mohamad, A. S., Khalid, M. H., Ming, O. H., Khalid, S., Tatt, L. M., Kamaldin, M. N., Zakaria, Z. A., Israf, D. A., Lajis, N., & Sulaiman, M. R. (2010). Zerumbone-Induced Antinociception: Involvement of the L-Arginine-Nitric Oxide-cGMP -PKC-K+ATP Channel Pathways. *Basic & clinical pharmacology & toxicology*, 108, 155–162.
- Petersen, M., Garg, U., & Ketha, H. (2020). Chapter 16 - Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. *Toxicology Cases for the Clinical and Forensic Laboratory*, 295-303.
- Petho, G., & Reeh, P. W. (2012). Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *Physiological reviews*, 92(4), 1699–1775.
- Picciotto, M. R., Higley, M. J., & Mineur, Y. S. (2012). Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. *Neuron*, 76(1), 116-129.
- Pithadia, A. B., & Jain, S. M. (2009). 5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. *Journal of clinical medicine research*, 1(2), 72–80.
- Polit, A., Rysiewicz, B., Paweł, M., Błasiak, E., & Dziejzicka-Wasylewska, M. (2020). The Gai protein subclass selectivity to the dopamine D2 receptor is also decided by their location at the cell membrane. *Cell Communication and Signaling*, 189.

- Pradhan, T., Jung, H. S., Jang, J. H., Kim, T. W., Kang, C., & Kim, J. S. (2014). Chemical sensing of neurotransmitters. *Chemical Society reviews*, 13.
- Pui Ping, C., Akhtar, M. N., Israf, D. A., Perimal, E. K., & Sulaiman, M. R. (2020). Possible Participation of Ionotropic Glutamate Receptors and I-Arginine-Nitric Oxide-Cyclic Guanosine Monophosphate-ATP-Sensitive K⁺ Channel Pathway in the Antinociceptive Activity of Cardamonin in Acute Pain Animal Models. *Molecules (Basel, Switzerland)*, 25(22), 5385.
- Qiao, L. N., Yang, Y. S., Liu, J. L., Zhu, J., Tan, L. H., Shi, Y. N., Zhu, B., & Rong, P. J. (2019). Contribution of GABAergic modulation in DRGs to electroacupuncture analgesia in incisional neck pain rats. *Journal of pain research*, 12, 405–416.
- Queiroz, J. C. C., Antonioli, Â. R., Quintans-Júnior, L. J., Brito, R. G., Barreto, R. S. S., Costa, E. V., da Silva, T. B., Prata, A. P. N., de Lucca, W., Almeida, J. R. G. S., Lima, J. T., & Quintans, J. S. S. (2014). Evaluation of the Anti-Inflammatory and Antinociceptive Effects of the Essential Oil from Leaves of *Xylopi* *laevigata* in Experimental Models. *The Scientific World Journal*, 2014, 816450.
- Quindere, A. L. G., Fontes, B. R., Vanderlei, E. d. S. O., de Queiroz, I. N. L., Rodrigues, J. A. G., de Araujo, I. W. F., Jorge, R. J. B., de Menezes, D. B., de Silva, A. A. R., Chaves, H. V., Evangelista, J. S. A. M., Bezerra, M. M., & Benevides, N. M. B. (2013). Peripheral antinociception and anti-edematogenic effect of a sulfated polysaccharide from *Acanthophora muscoides*. *Pharmacological Reports*(65), 600-613.
- Raffa, R. B., Pergolizzi, J. V., Taylor, R. J., Decker, J. F., & Patrick, J. T. (2014). Acetaminophen (Paracetamol) Oral Absorption and Clinical Influences. *Pain Practice*, 14(7).
- Rahim, M. H. A., Zakaria, Z. A., Sani, M. H. M., Omar, M. H., Yakob, M. S., Cheema, M. S., Ching, S. M., Ahmad, Z., & Kadir, A. A. (2016). Methanolic extract of *Clinacanthus nutans* exerts antinociceptive activity via the opioid/nitric oxide-mediated, but cGMP-independent, pathways. *Evidence-Based Complementary and Alternative Medicine*, 11.
- Rahmani, A. H., Alsahli, M. A., Aly, S. M., Khan, M. A., & Aldebasi, Y. H. (2018). Role of Curcumin in Disease Prevention and Treatment. *Advanced biomedical research*, 7(38).
- Ramana Reddy, S. V., & Yaksh, T. L. (1980). Spinal noradrenergic terminal system mediates antinociception. *Brain research*, 189(2), 391-401.
- Raphael, C. E., & Obioma, U. N. (2014). Acute and subacute oral toxicity study on the flavonoid rich fraction of *Monodora tenuifolia* seed in albino rats. *Asian Pacific Journal of Tropical Biomedicine*, 4(3), 194–202.

- Rensburg, R. V., & Reuter, H. (2019). An overview of analgesics: NSAIDs, paracetamol, and topical analgesics Part 1. *South African Family Practice*, 61, 4-10.
- Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. *Arteriosclerosis, thrombosis, and vascular biology*, 31(5), 986–1000.
- Rojas, P. S., & Fiedler, J. L. (2016). “What do we really know about 5-HT1A receptor signaling in neuronal cells?” *Frontiers in cellular neuroscience*, 10, 272.
- Rosa, A. C., & Fantozzi, R. (2013). The role of histamine in neurogenic inflammation. *British Journal of Pharmacology*(170), 38-45.
- Rosalia, C., Daniela, I., & Salvatore, C. (2019). Role of Metabotropic Glutamate Receptors in Neurological Disorders. *Frontiers in Molecular Neuroscience*, 12.
- Rothenberger, J., Wittwer, M., Tschumi, C., Constantinescu, M. A., Daigeler, A., & Olariu, R. (2019). Quantitative impact analysis of remote ischemic conditioning and capsaicin application on human skin microcirculation. *Clin Hemorheol Microcirc.*, 71, 291–298.
- Ruscheweyh, R., Wilder-Smith, O., Drdla, R., Liu, X. G., & Sandkühler, J. (2011). Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy. *Molecular pain*, 7(20).
- Rzasa Lynn, R., & Galinkin, J. L. (2018). Naloxone dosage for opioid reversal: current evidence and clinical implications. *Therapeutic advances in drug safety*, 9(1), 63–88.
- Sandoz, G., & Levitz, J. (2013). Optogenetic techniques for the study of native potassium channels. *Frontiers in Molecular Neuroscience*, 6(6).
- Sanger, G. J., & Andrews, P. L. R. (2018). A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research. *Front. Pharmacol.*
- Sani, M. H. M., Zakaria, Z. A., Balan, T., Teh, L. K., & Salleh, M. Z. (2012). Antinociceptive activity of methanol extract of *Muntingia calabura* leaves and the mechanisms of action involved. *Evidence-Based Complementary and Alternative Medicine*, 2012(890361), 10.
- Santos, A. R. S., Filho, V. C., Yunes, R. A., & Calixto, J. B. G. P. T. V. S. (1995). Analysis of the mechanisms underlying the antinociceptive effect of the extracts of plants from the genus *Phyllanthus*. *General Pharmacology: The Vascular System*(26), 1499-1506.
- Santos, A. R. S., Gadotti, V. M., Oliveira, G. L., Tibola, D., Paszcuk, A. F., Neto, A., Spindola, H. M., Souza, M. M., Rodrigues, A. L. S., & Calixto, J. B.

- (2005). Mechanisms involved in the antinociception caused by agmatine in mice. *Neuropharmacology*, 48, 1021-1034.
- Saulino, M. (2012). The use of intrathecal baclofen in pain management. *Pain Management*, 2, 603-608.
- Schjerning, A. M., McGettigan, P., & Gislason, G. (2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. *Nat Rev Cardiol*, 17, 574–584.
- Schmidtko, A., Tegeder, I., & Geisslinger, G. (2009). No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. *Trends in neurosciences*, 32(6), 339-346.
- Shaikh, G., & Cronstein, B. (2016). Signaling pathways involving adenosine A2A and A2B receptors in wound healing and fibrosis. *Purinergic signalling*, 12(2), 191–197.
- Shajib, M. S., & Khan, W. I. (2015). The role of serotonin and its receptors in activation of immune responses and inflammation. *Acta physiologica (Oxford, England)*, 213(3), 561–574.
- Sharifi-Rad, J., Rayess, Y. E., Rizk, A. A., Sadaka, C., Zgheib, R., Zam, W., Sestito, S., Rapposelli, S., Neffe-Skocińska, K., Zielińska, D., Salehi, B., Setzer, W. N., Dosoky, N. S., Taheri, Y., Martorell, M., Ostrander, E. A., Suleria, H., Cho, W. C., Maroyi, A., & Martins, N. (2020). Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. *Frontiers in pharmacology*, 11(1021). doi:10.3389/fphar.2020.01021
- Sharma, C. V., & Mehta, V. (2014). Paracetamol: mechanisms and updates. *BJA Education*, 14(4), 153-158.
- Sharma, J. N., & Al-Banoon, A. (2012). The Role of Inflammatory Mediator Bradykinin in Cardiovascular and Renal Diseases. *Open Access Scientific Reports*, 1(2).
- Shaye, H., Stauch, B., Gati, C., & Cherezov, V. (2021). Molecular mechanisms of metabotropic GABAB receptor function. *Science Advances*, 7(22).
- Silva, E., Quiñones, B., Freund, N., Gonzalez, L. E., Hernandez, L., & (2001). . (2001). Extracellular glutamate, aspartate and arginine increase in the ventral posterolateral thalamic nucleus during nociceptive stimulation. *Brain Research*, 923(1-2), 45-49.
- Smutzer, G., & Devassy, R. K. (2016a). Integrating TRPV1 Receptor Function with Capsaicin Psychophysics. *Advances in pharmacological sciences*, 1512457.
- Smutzer, G., & Devassy, R. K. (2016b). Integrating TRPV1 Receptor Function with Capsaicin Psychophysics. *Advances in Pharmacological Sciences*.

- Sneddon, L. U. (2017). Comparative Physiology of Nociception and Pain. *Physiology*, 33, 63-73.
- Sola, D., Rossi, L., Schianca, G. P., Maffioli, P., Bigliocca, M., Mella, R., Corliano, F., Fra, G. P., Bartoli, E., & Derosa, G. (2015). Sulfonylureas and their use in clinical practice. *Archives of medical science : AMS*, 11(4), 840–848.
- Staud, R. (2014). The important role of CNS facilitation and inhibition for chronic pain. *The International Journal of Clinical Rheumatology*, 8(6), 639-646.
- Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C., & Bunnett, N. W. (2014). Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. *Physiological reviews*, 94(1), 265–301.
- Su, Y. S., Chiu, Y. Y., Lin, S. Y., Chen, C. C., & Sun, W. H. (2016). Serotonin Receptor 2B Mediates Mechanical Hyperalgesia by Regulating Transient Receptor Potential Vanilloid 1. *Journal of molecular neuroscience*, 59(113–125).
- Sudo, R. T., Amaral, R. V. D., Monteiro, C. E. S., Pitta, I. D. R., Lima, M. D. C., Montes, G. C., Ririe, D. G., Hayashida, K., & Zapata-Sudo, G. (2017). Antinociception induced by a novel $\alpha 2A$ adrenergic receptor agonist in rodents acute and chronic pain models. *European Journal of Pharmacology*, 815, 210-218.
- Sulaiman, M. R., Padzil, A. M., Shaari, K., Khalid, S., Mossadeq, W. M. S., Mohamad, A. S., Ahmad, S., Akira, A., Israf, D., & Lajis, N. (2011). Antinociceptive Activity of Melicope ptelefolia Ethanolic Extract in Experimental Animals. *Biomedicine and Biotechnology*.
- Suvas, S. (2017). Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis. *J Immunol*, 199(5), 1543-1552.
- Svoboda, J., Popelikova, A., & Stuchlik, A. (2017). Drugs Interfering with Muscarinic Acetylcholine Receptors and Their Effects on Place Navigation. *Frontiers in psychiatry*, 8, 215.
- Takayama, Y., Derouiche, S., Maruyama, K., & Tominaga, M. (2019). Emerging Perspectives on Pain Management by Modulation of TRP Channels and ANO1. *International journal of molecular sciences*, 20(14), 3411.
- Tao, Z. Y., Wang, P. X., Wei, S. Q., Traub, R. J., Li, J. F., & Cao, D. Y. (2019). The Role of Descending Pain Modulation in Chronic Primary Pain: Potential Application of Drugs Targeting Serotonergic System. *Neural Plasticity*, 2019.
- Thakre, P. P., & Bellingham, M. C. (2017). Capsaicin Enhances Glutamatergic Synaptic Transmission to Neonatal Rat Hypoglossal Motor Neurons via

- a TRPV1-Independent Mechanism. *Frontiers in cellular neuroscience*, 11(383).
- Tham, C. L., Liew, C. Y., Lam, K. Y., Mohamad, A. S., Kim, M. K., Cheah, Y. K., Zakaria, Z. A., Sulaiman, M. R., Lajis, N. H., & Israf, D. A. (2010). A Synthetic Curcuminoid Derivative Inhibits Nitric Oxide and Proinflammatory Cytokine Synthesis. *European Journal of Pharmacology*, 628, 247-254.
- Thangam, E. B., Jemima, E. A., Singh, H., Baig, M. S., Khan, M., Mathias, C. B., Church, M. K., & Saluja, R. (2018). The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. 9(1873).
- Thinkratok, A., Suwannaprapha, P., & Srisawat, R. (2014). Safety assessment of hydroethanolic rambutan rind extract: acute and sub-chronic toxicity studies. *Indian Journal of Experimental Biology*, 52(10), 989-995.
- Thompson, A. J., & Lummis, S. C. (2007). The 5-HT₃ receptor as a therapeutic target. *Expert opinion on therapeutic targets*. 11(4), 527–540.
- Thomsen, M., Sørensen, G., & Dencker, D. P. r. o. C. m. r. g. f. k. m. N., 136(Pt C), 411–420 (2018). Physiological roles of CNS muscarinic receptors gained from knockout mice. *Neuropharmacology*. *Neuropharmacology*, 136(Pt C), 411–420.
- Tilahun, A. N., Mekbeb, A., Kelbessa, U., Wondwossen, E., & Eyasu, M. (2017). Toxicological investigation of acute and chronic treatment with *Gnidia stenophylla* Gilg root extract on some blood parameters and histopathology of spleen, liver and kidney in mice. *BMC Research Notes*, 10, 625.
- Trescot, A. M., Datta, S., Lee, M., & Hansen, H. (2008). Opioid pharmacology. *Pain Physician*, 11, S133-153.
- TrivellatoGrassi, L., Malheiros, A., Meyre-Silva, C., da Silva Buss, Z., Monguilhott, E. D., Frode, T. S., da Silva, K. A. B. S., & de Souza, M. M. (2013). From popular use to pharmacological validation: A study of the anti-inflammatory, anti-nociceptive and healing effects of *Chenopodium ambrosioides* extract. *Journal of Ethnopharmacology*(145), 127-138.
- Tsantoulas, C., & McMahon, S. B. (2014). Opening paths to novel analgesics: the role of potassium channels in chronic pain. *Trends in Neurosciences*(37), 146-158.
- Turner, P. V., Brabb, T., Pekow, C., & Vasbinder, M. A. (2011). Administration of substances to laboratory animals: routes of administration and factors to consider. *Journal of the American Association for Laboratory Animal Science : JAALAS*, 50(5), 600–613.

- Vincenzi, F., Pasquini, S., Borea, P. A., & Varani, K. (2020). Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain. *International journal of molecular sciences*, 21(22), 8710.
- Wallace, M. S., Lam, V., & Schettler, J. (2012). NGX426, an Oral AMPA-Kainate Antagonist, Is Effective in Human Capsaicin-Induced Pain and Hyperalgesia. *Pain Medicine*, 13(12), 1601-1610.
- Wang, Y., Tan, B., Wang, Y., & Chen, Z. (2021). Cholinergic Signaling, Neural Excitability, and Epilepsy. *Molecules*, 26.
- Weatherall, K., Goodchild, S., Jane, D., & Marrion, N. (2010). Small conductance calcium-activated potassium channels: From structure to function. *Progress in neurobiology*, 91(3), 242-255.
- Westhuizen, V. D. E. T., Choy, K., Valant, C., McKenzie-Nickson, S., Bradley, S. J., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2021). Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allosterity and Bias. *Frontiers in pharmacology*, 11, 606656.
- Woller, S. A., Eddinger, K. A., Corr, M., & Yaksh, T. L. (2017). An overview of pathways encoding nociception. *Clinical and experimental rheumatology*, 107(5), 40–46.
- Wong, V. W., & Lerner, E. (2015). Nitric oxide inhibition strategies. *Future science OA*, 1(1).
- Wongrakpanich, S., Wongrakpanich, A., Melhado, K., & Rangaswami, J. (2018). A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. *Aging and disease*. 9(1), 143–150.
- Woodling, N. S., Colas, D., Wang, Q., Minhas, P., Panchal, M., Liang, X., Mhatre, S. D., Brown, H., Ko, N., Zagol-Ikapitte, I., van der Hart, M., Khroyan, T. V., Chuluun, B., Priyam, P. G., Milne, G. L., Rassoulpour, A., Boutaud, O., Manning-Boğ, A. B., Heller, H. C., & Andreasson, K. I. (2016). Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. *Brain : a journal of neurology*, 139(7), 2063–2081.
- Woolf, C. J. (2004). Pain: moving from symptom control toward mechanism-specific pharmacologic management. *Annals of internal medicine*, 140(6), 441.
- Wozniak, K. M., Rojas, C., Wu, Y., & Slusher, B. S. (2012). The Role of Glutamate Signaling in Pain Processes and its Regulation by GCP IIIinhibition. *Current Medicinal Chemistry*, 19, 1323-1334.
- Wu, Y., Liu, Y., Hou, P., Yan, Z., Kong, W., Liu, B., Li, X., Yao, J., Zhang, Y., & Qin, F. (2013). TRPV1 channels are functionally coupled with BK (mSlo1) channels in rat dorsal root ganglion (DRG) neurons., 8(10).

- Xie, S. S., Fan, W. G., Liu, Q., Li, J. Z., Zheng, M. M., He, H. W., & Huang, F. (2020). Involvement of nNOS in the antinociceptive activity of melatonin in inflammatory pain at the level of sensory neurons. *European Review for Medical and Pharmacological Sciences*, 24(13), 7399–7411.
- Xie, W. (2011). Assessment of Pain in Animals. In C. Ma & J.-M. Zhang (Eds.), *Animal Models of Pain* (Vol. 49, pp. 14-34). Spring Street, New York, USA: Humana Press, Springer Science+Business Media.
- Yadav, P., & Purohit, N. V. (2013). Synthesis and evaluation of some bioactive compounds having oxygen and nitrogen heteroatom. *Journal of Chemical Sciences*, 125(1), 165-173.
- Yam, M. F., Loh, Y. C., Oo, C. W., & Basir, R. (2020). Overview of Neurological Mechanism of Pain Profile Used for Animal "Pain-Like" Behavioral Study with Proposed Analgesic Pathways. *International journal of molecular sciences*, 21(12), 4355.
- Yam, M. F., Loh, Y. C., Tan, C. S., Khadijah Adam, S., Abdul Manan, N., & Basir, R. (2018). General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation. *International journal of molecular sciences*, 19(8), 2164.
- Yang, Y. (2021). Functional Selectivity of Dopamine D1 Receptor Signaling: Retrospect and Prospect. *International journal of molecular sciences*, 22, 11914.
- Yin, Z. Y., Li, L., Chu, S. S., Sun, Q., Ma, Z. L., & Gu, X. P. (2016). Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. *Scientific Reports*, 6.
- Yui, K., Imataka, G., Nakamura, H., Ohara, N., & Naito, Y. (2015). Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders. *Current Neuropharmacology*, 13(6), 776-785.
- Zakaria, Z. A., Abdul Rahim, M. H., Roosli, R., Mohd Sani, M. H., Omar, M. H., Mohd Tohid, S. F., Othman, F., Ching, S. M., & Abdul Kadir, A. (2018). Antinociceptive Activity of Methanolic Extract of *Clinacanthus nutans* Leaves: Possible Mechanisms of Action Involved. *Pain research & management*, 2018, 9536406.
- Zakaria, Z. A., Sani, M. H. M., Kadir, A. A., Kek, T. L., & Salleh, M. Z. (2016). Antinociceptive effect of semi-purified petroleum ether partition of *Muntingia calabura* leaves. *Revista Brasileira de Farmacognosia*, 26, 408–419.
- Zeilhofer, H. U., Wildner, H., & Yévenes, G. E. (2012). Fast synaptic inhibition in spinal sensory processing and pain control. *Physiological reviews*, 92(1), 193–235.

- Zeitz, K. P., Guy, N., Malmberg, A. B., Dirajlal, S., Martin, W. J., Sun, L., Bonhaus, D. W., Stucky, C. L., Julius, D., & Basbaum, A. I. (2002). The 5-HT₃ subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. *The Journal of neuroscience*, 22.
- Zhang, Y., Kolli, T., Hivley, R., Jaber, L., Zhao, F. I., Yan, J., & Herness, S. (2010). Characterization of the expression pattern of adrenergic receptors in rat taste buds. *Neuroscience*, 169(3), 1421–1437.
- Zhang, Y. Q., Gao, X., Zhang, L. M., & Wu, G. C. (2000). The release of serotonin in rat spinal dorsal horn and periaqueductal gray following carrageenan inflammation. *Neuroreport*, 11(16), 3539.
- Zhou, H. Y., Chen, S. R., & Pan, H. L. (2011). Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain. *Expert review of clinical pharmacology*, 4(3), 379–388.
- Zulazmi, N. A., Gopalsamy, B., Min, J. C. S., Farouk, A. A. O., Sulaiman, M. R., Bharatham, B. H., & Perimal, E. K. (2017). Zerumbone Alleviates Neuropathic Pain through the Involvement of I-Arginine-Nitric Oxide-cGMP-K⁺ ATP Channel Pathways in Chronic Constriction Injury in Mice Model. 22(4), 555.